<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Asian Pac J Cancer Prev</journal-id><journal-id journal-id-type="iso-abbrev">Asian Pac. J. Cancer Prev</journal-id><journal-title-group><journal-title>Asian Pacific Journal of Cancer Prevention : APJCP</journal-title></journal-title-group><issn pub-type="ppub">1513-7368</issn><issn pub-type="epub">2476-762X</issn><publisher><publisher-name>West Asia Organization for Cancer Prevention</publisher-name><publisher-loc>Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6171375</article-id><article-id pub-id-type="pmid">30139042</article-id><article-id pub-id-type="publisher-id">APJCP-19-2057</article-id><article-id pub-id-type="doi">10.22034/APJCP.2018.19.8.2057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elfaki</surname><given-names>Imadeldin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mir</surname><given-names>Rashid</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Almutairi</surname><given-names>Fahad M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Duhier</surname><given-names>Faisel M Abu</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Department of Biochemistry, Faculty of Science, University of Tabuk, Kingdom of Saudi Arabia</italic></aff><aff id="aff2"><label>2</label><italic>Prince Fahd Ben Sultan Research Chair, Department of Medical Lab Technology, Faculty of Applied Medical Sciences, University of Tabuk, Kingdom of Saudi Arabia</italic></aff><author-notes><corresp id="cor1"><label>*</label><italic>For Correspondence: <email xlink:href="ielfaki@ut.edu.sa">ielfaki@ut.edu.sa</email></italic></corresp></author-notes><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>19</volume><issue>8</issue><fpage>2057</fpage><lpage>2070</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>Copyright: Â© Asian Pacific Journal of Cancer Prevention</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/BY-SA/4.0"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Cytochromes P450s (CYPs) constitute a superfamily of enzymes that catalyze the metabolism of drugs and other substances. </plain></SENT>
<SENT sid="2" pm="."><plain>Endogenous substrates of CYPs include eicosanoids, estradiol, arachidonic acids, cholesterol, vitamin D and neurotransmitters. </plain></SENT>
<SENT sid="3" pm="."><plain>Exogenous substrates of CYPs include the polycyclic aromatic hydrocarbons and about 80% of currently used drugs. </plain></SENT>
<SENT sid="4" pm="."><plain>Some isoforms can activate procarcinogens to ultimate carcinogens. </plain></SENT>
<SENT sid="5" pm="."><plain>Genetic polymorphisms of CYPs may affect the enzyme catalytic activity and have been reported among different populations to be associated with various diseases and adverse drug reactions. </plain></SENT>
<SENT sid="6" pm="."><plain>With regard of drug metabolism, phenotypes for CYP polymorphism range from ultrarapid to poor metabolizers. </plain></SENT>
<SENT sid="7" pm="."><plain>In this review, we discuss some of the most clinically important CYPs isoforms (CYP2D6, CYP2A6, CYP2C19, CYP2C9, CYP1B1 and CYP1A2) with respect to gene polymorphisms and drug metabolism. </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, we review the role of CYPs in renal, lung, breast and prostate cancers and also discuss their significance for atherosclerosis and type 2 diabetes mellitus. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>CytochromeP450</kwd><kwd>polymorphism</kwd><kwd>T2D</kwd><kwd>Atherosclerosis</kwd><kwd>drug metabolism</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec1-1"><title><text><SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>The cytochrome P450 (CYP) is a large superfamily of integral membrane conserved proteins present in animals, plants, and microorganisms (Nebert and Russell, 2002). </plain></SENT>
<SENT sid="11" pm="."><plain>The CYP isoenzyme superfamily comprises 57 CYP genes and 58 pseudogenes arranged into 18 families and 43 subfamilies in man (Nelson et al., 2004). </plain></SENT>
<SENT sid="12" pm="."><plain>They are heme-containing proteins that catalyze the oxidative metabolism of many structurally diverse drugs and chemicals (Woo et al., 2002). </plain></SENT>
<SENT sid="13" pm="."><plain>The reduced cytochrome P450 isoenzymes when bound to CO has a Soret peak at 450 nm (Luthra et al., 2011). </plain></SENT>
<SENT sid="14" pm="."><plain>This peak is not usual for a hem containing protein molecule. </plain></SENT>
<SENT sid="15" pm="."><plain>Hence, they are called P450 (Luthra et al., 2011). </plain></SENT>
<SENT sid="16" pm="."><plain>In mammals, the CYPs system is expressed in all tissues examined (Porter and Coon, 1991). </plain></SENT>
<SENT sid="17" pm="."><plain>They are expressed predominately in the endoplasmic reticulum membrane as well as in other cellular compartments such as the cell surface and in mitochondria (Neve and Ingelman-Sundberg, 2010). </plain></SENT>
<SENT sid="18" pm="."><plain>The cytochrome P450 superfamily is located primarily in liver, small intestine and kidney (Thelen and Dressman, 2009; Renaud et al., 2011). </plain></SENT>
<SENT sid="19" pm="."><plain>CYPs P450 enzymes catalyze different oxidation and some reduction reactions (Guengerich, 2007). </plain></SENT>
<SENT sid="20" pm="."><plain>Examples of the substrates (Porter and Coon, 1991; Chang and Kam, 1999) of CYPs include exogenous (xenobiotics) and endogenous compounds such as cholesterol, testosterone, progesterone, prostagalandin H2, corticosterone, retinoic acid, vitamin D3 and arachidonic acid (Guengerich, 2017). </plain></SENT>
</text></p><sec id="sec2-1"><title><text><SENT sid="21" pm="."><plain>Nomenclature and Mechanism of Action of Cytochrome P450 </plain></SENT>
</text></title><p><text><SENT sid="22" pm="."><plain>CYPs are grouped into families and subfamilies according to the similarity of amino acid sequence. </plain></SENT>
<SENT sid="23" pm="."><plain>The enzyme code is started with the CYP followed by a designating number for the family (Petersson, 2009; Sim and Ingelman-Sundberg, 2010; Sim and Ingelman-Sundberg, 2013). </plain></SENT>
<SENT sid="24" pm="."><plain>Then, a letter for the subfamily and ending with an individual number for the gene (Petersson, 2009). </plain></SENT>
<SENT sid="25" pm="."><plain>If the CYPs enzymes share more than 40 % identity in amino acid sequence they will be group in the same family, for example (CYP2). </plain></SENT>
<SENT sid="26" pm="."><plain>If the identity is more than 55%, the CYP enzymes belong to the same subfamily for example CYP2A. </plain></SENT>
<SENT sid="27" pm="."><plain>Then the CYP enzyme will be given an individual number, for example CYP2A6. </plain></SENT>
<SENT sid="28" pm="."><plain>An up to date list of CYP is found on a CYP 450 homepage (<ext-link ext-link-type="uri" xlink:href="https://www.pharmvar.org/gene/index_original">https://www.pharmvar.org/gene/index_original</ext-link>) (Sim and Ingelman-Sundberg, 2010; Sim and Ingelman-Sundberg, 2013). </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>All CYP enzymes share a conserved general three dimensional structure that resembles a shape of an inverted triangle (Petersson, 2009). </plain></SENT>
<SENT sid="30" pm="."><plain>The CYP enzyme consists of a protein moiety and a heme (iron protoporphyrin IX) as prosthetic group of the enzyme (Ortiz de Montellano, 2010). </plain></SENT>
<SENT sid="31" pm="."><plain>They are involved in the metabolism of the lipophilic endogenous and xenobiotic compounds transform them to hydrophilic or polar compounds such that they can be easily excreted from the body (Chang and Kam, 1999). </plain></SENT>
<SENT sid="32" pm="."><plain>The biotransformation reactions are divided into two phases. </plain></SENT>
<SENT sid="33" pm="."><plain>The CYPs catalyze the phase 1 reactions (Sim and Ingelman-Sundberg, 2013), which are oxidation or demethylation (Iyanagi, 2007). </plain></SENT>
<SENT sid="34" pm="."><plain>The substrate binds the catalytic pocket of the CYP enzyme that contains heme iron. </plain></SENT>
<SENT sid="35" pm="."><plain>The heme iron is then reduced from the ferric to the ferrous state by an electron transferred from a reduced NADPH (Chang and Kam, 1999). </plain></SENT>
<SENT sid="36" pm="."><plain>The molecular oxygen then binds temporarily at heme containing active site (Zanger and Schwab, 2013). </plain></SENT>
<SENT sid="37" pm="."><plain>Thereafter, one oxygen atom is inserted in the substrate molecule and the other atom is reduced to form H2O. </plain></SENT>
<SENT sid="38" pm="."><plain>The reaction for the monooxygenation can be represented in the formula: RH + NAD (P) H + O2 + H+ -&gt; ROH + NAD (P) + H2O. </plain></SENT>
<SENT sid="39" pm="."><plain>Where, RH is the substrate containing a hydroxylatable site. </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>CYP enzymes therefore belong to the enzymes class of monooxygenase that only incorporates one atom of the molecular oxygen into their substrates (Ortiz de Montellano, 2010). </plain></SENT>
<SENT sid="41" pm="."><plain>The major functions of CYPs are the metabolism of the foreign compounds. </plain></SENT>
<SENT sid="42" pm="."><plain>For instance, they catalyze the hydroxylation of the drugs barbiturate and the phenobarbital (Zanger and Schwab, 2013) to increase their hydrophilicity such that they can be eliminated via the kidney. </plain></SENT>
<SENT sid="43" pm="."><plain>Other examples of drugs that are metabolized by the oxidation catalyzed by CYPs are the ibuprofen and the caffeine (Zanger and Schwab, 2013). </plain></SENT>
<SENT sid="44" pm="."><plain>Therefore, duration of action of many drugs depends on their rate of metabolism by the CYPs enzymes (Fernandez et al., 2011). </plain></SENT>
<SENT sid="45" pm="."><plain>The polycyclic aromatic hydrocarbons (PAHs)Â° are wide spreading environmental procarcinogens that inducetumorigenesis when they are activated by CYPs 450 and other enzymes such as epoxide hydrolase, and aldoketoreductase (Shimada et al., 2008; Moorthy et al., 2015). </plain></SENT>
<SENT sid="46" pm="."><plain>The PAHs activation results in the formation of the reactive and redox-active o-quinones, diolepoxides, or radical cations (Moorthy et al., 2015). </plain></SENT>
<SENT sid="47" pm="."><plain>All of these compounds react with the DNA and forming DNA adducts. </plain></SENT>
<SENT sid="48" pm="."><plain>The DNA adducts eventually lead to the mutation and initiation of the carcinogenesis (Moorthy et al., 2015). </plain></SENT>
<SENT sid="49" pm="."><plain>For instance, it has been reported that CYP1B1 that is found in pulmonary and other tissues (except for liver) has a pivotal role in the metabolic activation of the PAHs (Shimada and Fujii-Kuriyama, 2004; Chun and Kim, 2016). </plain></SENT>
<SENT sid="50" pm="."><plain>The PAHs that are metabolically activated by the CYP1B1 and CYP1A1 are the Benzo[a]pyrene, dibenzo[a]pyrene, 7,12-dimethylbenz[a]anthracene, 5-methylchrysene (Shimada et al., 2001). </plain></SENT>
</text></p></sec><sec id="sec2-2"><title><text><SENT sid="51" pm="."><plain>Role of CytochromeP450 in Cancers </plain></SENT>
</text></title></sec><sec id="sec2-3"><title><text><SENT sid="52" pm="."><plain>A- Renal cancer </plain></SENT>
</text></title><p><text><SENT sid="53" pm="."><plain>The cytochrome P450 (CYP3A) forms was shown to be expressed consistently in kidney cancer cells using the immunohistochemistry, western blot analysis, and reverse transcriptase PCR (Murray et al., 1999). </plain></SENT>
<SENT sid="54" pm="."><plain>This study has suggested that the expressed CYP3A may be involved in renal cancer development (Murray et al., 1999), and that these forms of CYP3A are the cause of the multidrug resistance observed in this cancer. </plain></SENT>
<SENT sid="55" pm="."><plain>Moreover, they proposed that the presence CYP3A forms in the renal cells is of benefit for the treatment of renal cancer. </plain></SENT>
<SENT sid="56" pm="."><plain>For instance, the agent AQ4N, an alkylaminoanthroquinone is bioactivated by CYP3A forms to a highly cytotoxic metabolite in the hypoxic conditions of the tumor cells, but the AQ4N would not be cytotoxic for the normal cells where the conditions are normoxic (Murray et al., 1999). </plain></SENT>
<SENT sid="57" pm="."><plain>The cytochrome CYP1B1 was also shown to be present in renal cell carcinoma (McFadyen et al., 2004). </plain></SENT>
<SENT sid="58" pm="."><plain>It is also expressed in wide variety of cancers and not detected in normal cells (Murray et al., 1997; McFadyen et al., 2004). </plain></SENT>
<SENT sid="59" pm="."><plain>It has been proposed that since CYP1B1 is the metabolizing enzyme for the anticancer drugs (e.g. cyclophosphamide, paclitaxel, doxorubicin, docetaxel, cisplatin, 5-fluorouracil) its inhibition may be a good strategy for cancer therapy (McFadyen et al., 2001). </plain></SENT>
<SENT sid="60" pm="."><plain>Recently, it has been suggested CYP1B1 is significantly unregulated in renal cell carcinoma, and that it promotes this cancer progression (Mitsui et al., 2015). </plain></SENT>
<SENT sid="61" pm="."><plain>This study has demonstrated that in renal cell carcinoma cell line attenuating the expression of the CYP1B1 gene results in inhibition of the cancer cell viability, migration, and invasiveness (Mitsui et al., 2015). </plain></SENT>
<SENT sid="62" pm="."><plain>Moreover, Mitsui et al., (2015) have reported that the expression of the CYP1B1 is positively correlates with the expression of the cell division cycle 20 homolog (CDC20). </plain></SENT>
<SENT sid="63" pm="."><plain>The CDC20 is an essential factor that drives mitotic phase through activation of anaphase-promoting complex /cyclosome (APC/C) that triggers the transition from metaphase to anaphase (Izawa and Pines, 2011). </plain></SENT>
<SENT sid="64" pm="."><plain>In addition, Mitsui et al (2015) have suggested that the CYP1B1 promotes renal cell cancer through down regulation of the death-associated protein kinase-1 (DAPK1). </plain></SENT>
<SENT sid="65" pm="."><plain>DAPK1 is a tumor suppressor gene and its expression is down regulated in many types of carcinoma (Chuang et al., 2008). </plain></SENT>
</text></p></sec><sec id="sec2-4"><title><text><SENT sid="66" pm="."><plain>B- Breast Cancer (BC) </plain></SENT>
</text></title><p><text><SENT sid="67" pm="."><plain>It has been reported that CYP2E1 contribute to the generation of the reactive oxygen species (ROS) in breast cancer cells (Leung et al., 2013). </plain></SENT>
<SENT sid="68" pm="."><plain>In addition, CYP2E1 regulates autophagy, stimulate stress of endoplasmic reticulum and suppress metastatic potential of the BC cells (Leung et al., 2013). </plain></SENT>
<SENT sid="69" pm="."><plain>The expression of the CYP2E1 was shown to increase significantly in BC cells as well as the tissues that are adjacent to the tumor (Vaclavikova et al., 2007). </plain></SENT>
<SENT sid="70" pm="."><plain>The overexpression of the CYP2E1 enzyme might be beneficial for the cancer patient (Vaclavikova et al., 2007). </plain></SENT>
<SENT sid="71" pm="."><plain>This benefit comes from CYP2E1 prodrugs activation property and that the metabolism of some substrates of CYP2E1 leads to the production of ROS and oxidative stress (Gonzalez, 2005). </plain></SENT>
<SENT sid="72" pm="."><plain>This eventually lead to the inhibition of the apoptosis but the necrotic cancer cell death will be accelerated (Gonzalez, 2005; Vaclavikova et al., 2007). </plain></SENT>
<SENT sid="73" pm="."><plain>In a study aimed to examine the expression profile of CYP450 enzymes in (BC) in Caucasian population (Murray et al., 2010), it has been reported that there are upregulations of the CYP4X1, CYP2S1 and CYP2U1. </plain></SENT>
<SENT sid="74" pm="."><plain>Moreover, the CYP1B1, CYP3A5 and CYP51 displayed significant correlations with cancer grade (Murray et al., 2010). </plain></SENT>
<SENT sid="75" pm="."><plain>CYP2S1 is involved in metabolism of important exogenous and endogenous substrates, for example, the retinoic acid that is a metabolite of vitamin A (Madanayake et al., 2013). </plain></SENT>
<SENT sid="76" pm="."><plain>CYP2S1 may also be involved in activation or deactivation of procarcinogens. </plain></SENT>
<SENT sid="77" pm="."><plain>The expression of CYP2S1 is comparable to that of the CYP1B1 (Rivera et al., 2007). </plain></SENT>
<SENT sid="78" pm="."><plain>In addition to tumors, the expression of CYP2S1 is also increased in myocardial infarction, lung hypertension, renal failure and rheumatoid arthritis. </plain></SENT>
<SENT sid="79" pm="."><plain>This increased expression probably influences the response of these pathological conditions to the treating drugs that are substrate of CYP2S1 (Rivera et al., 2007). </plain></SENT>
<SENT sid="80" pm="."><plain>Other study has reported that the CYP3A is not expressed in Japanese BC patients and that CYP3A expression in BC population may be of ethnic dependent (Oyama et al., 2005). </plain></SENT>
<SENT sid="81" pm="."><plain>Studying the expression of CYP3A in BC is of special interest since the tamoxifen is metabolized by CYP3A. </plain></SENT>
<SENT sid="82" pm="."><plain>The efficacy of tamoxifen treatment is influenced by variation in CYP3A expression (Oyama et al., 2005). </plain></SENT>
</text></p></sec><sec id="sec2-5"><title><text><SENT sid="83" pm="."><plain>C-Lung Cancer </plain></SENT>
</text></title><p><text><SENT sid="84" pm="."><plain>CYP2A13 belongs to the member of the Â°CYP2AÂ° subfamily and it has been shown that it is expressed predominantly in the respiratory tract, brain, mammary gland, prostate, testicles, and uterus (Zhu et al., 2006). </plain></SENT>
<SENT sid="85" pm="."><plain>The highest expression quantified by PCR was in the nasal mucosa, trachea, and lung tissues (Su et al., 2000; Sun and Fan, 2013). </plain></SENT>
<SENT sid="86" pm="."><plain>CYP2A13 catalyzes the metabolic activation of the major tobacco-specific carcinogen, the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NMK) through alpha hydroxylation (Su et al., 2000). </plain></SENT>
<SENT sid="87" pm="."><plain>It has been shown that there is down-regulation of CYP2A13 expression in adenocarcinoma and suggested that CYP2A13 is implicated in the development and progression of lung adenocarcinoma (Sun and Fan, 2013). </plain></SENT>
</text></p><p><text><SENT sid="88" pm="."><plain>It has been suggested that there is association between estrogen metabolism and cigarette smoking and there is growing evidences proposing that estrogen levels is elevated in lung cancer (Chakraborty et al., 2010; Slowikowski et al; 2017). </plain></SENT>
<SENT sid="89" pm="."><plain>CYP1B1 is induced by tobacco (Port et al., 2004), and can convert the tobacco procarcinogens benzo[a]pyrene (B[a]P) to carcinogenic intermediates (Port et al., 2004). </plain></SENT>
<SENT sid="90" pm="."><plain>Estrogen also is metabolized with CYP1B1 (Samavat and Kurzer, 2015). </plain></SENT>
<SENT sid="91" pm="."><plain>In lung tissues during the metabolism of the estradiol and the tobacco specific carcinogens by CYP1B1, DNA adducts and ROS can form which may cause DNA damage which can be mutagenic (Slowikowski et al., 2017). </plain></SENT>
<SENT sid="92" pm="."><plain>It has been shown that there are lower expressions of CYP1B1 in non-small cell lung cancer at both mRNA and protein levels in the middle stage of non-small cell lung cancer (NSCLC) irrespective of the age, gender or the histopathological type of lung cancer (Slowikowski et al., 2017). </plain></SENT>
<SENT sid="93" pm="."><plain>However, there is overexpression of CYP1B1 in advanced cases of NSCLC (Su et al., 2009). </plain></SENT>
<SENT sid="94" pm="."><plain>The gene polymorphism of CYP1B1 Leu432Val was associated with increased lung cancer risk in nonsmokers (Wenzlaff et al., 2005). </plain></SENT>
</text></p></sec><sec id="sec2-6"><title><text><SENT sid="95" pm="."><plain>D-Prostate Cancer (PC) </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>It has been shown with real time PCR and western blot analysis that the CYP3A5 is the most expressed CYP isoform in basolateral cells of normal prostate tissue, but not expressed tumor cells (Leskela et al., 2007). </plain></SENT>
<SENT sid="97" pm="."><plain>LeskelÃ¤ et al., (2007) reported that the amount of CYP3A5 mRNA expressed in normal prostate cells was about 20% of the amount present in hepatic tissue. </plain></SENT>
<SENT sid="98" pm="."><plain>This study suggested that CYP3A5 functions in metabolism of intra-prostatic androgens and promotes luminal cell growth, and that gene polymorphisms in CYP3A5 are associated with PC risk and aggressiveness (Leskela et al., 2007). </plain></SENT>
<SENT sid="99" pm="."><plain>CYP1B1 has been shown to be overexpressed in PC cells and this overexpression is caused by hypomethylation of promoter/enhancer of the CYP1B1 gene (Tokizane et al., 2005). </plain></SENT>
<SENT sid="100" pm="."><plain>It is proposed that CYP1B1 is implicated in prostate carcinogenesis by its ability to activate metabolic carcinogens, as there is association between exposure to PAHs and increased risk to PC (Tokizane et al., 2005). </plain></SENT>
<SENT sid="101" pm="."><plain>CYP1A1 is involved in metabolism of estrogen and can activate procarcinogens (He and Feng, 2015). </plain></SENT>
<SENT sid="102" pm="."><plain>It has been reported that CYP1A1 polymorphism is associated with PC development (Ding et al., 2013). </plain></SENT>
<SENT sid="103" pm="."><plain>In a study conducted in Indian cohort reported that CYP1A1 gene polymorphism that leads to Ile462Val change was associated with a reduced PC risk, while polymorphism T3801C at 3âUTR of CYP1A1 gene was associated with increased PC risk (Vijayalakshmi et al., 2005). </plain></SENT>
<SENT sid="104" pm="."><plain>Furthermore, it has been suggested that CYP27B1 controls the normal growth of prostate cells through its role in vitamin D metabolism (Chen et al., 2012), and that CYP27B1 is regulated by epidermal growth factor (Chen et al., 2012). </plain></SENT>
<SENT sid="105" pm="."><plain>CYP27B1 has anti-tumor activity and when desregulated by epidermal growth factor the PC develops (Chen, 2008; Chen et al., 2012). </plain></SENT>
<SENT sid="106" pm="."><plain>Another CYP isoform of interest in PC is CYP17A1. </plain></SENT>
<SENT sid="107" pm="."><plain>CYP17A1 is involved in androgen biosynthesis and has been implicated in PC proliferation (Gomez et al., 2015). </plain></SENT>
<SENT sid="108" pm="."><plain>The use of CYP17A1 inhibitors (such as abiraterone acetate) is a recent strategy for treatment of castration-resistant PC (Gomez et al., 2015). </plain></SENT>
</text></p></sec><sec id="sec2-7"><title><text><SENT sid="109" pm="."><plain>Roles of CytochromeP450 in Diabetes </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>CYP2E1 is induced by and oxidize ethanol, and it activates procarcinogens such as N-nitrosodimethylamine, benzene and N-alkylformamides (Wang et al., 2003). </plain></SENT>
<SENT sid="111" pm="."><plain>It has been shown that CYP2E1 is overexpressed in alcohol-induced liver damage as well as non-alcoholic steatosis (Niemela et al., 2000). </plain></SENT>
<SENT sid="112" pm="."><plain>Diabetes is commonly associated with fat mobilization as it will be the first energy source which will lead to the development of non-alcoholic fatty liver disease (Hazlehurst et al., 2016). </plain></SENT>
<SENT sid="113" pm="."><plain>It has been shown that there is elevated activity of CYP2E1 in liver of obese Type 2 diabetic patients (Wang et al., 2003). </plain></SENT>
<SENT sid="114" pm="."><plain>It is hypothesized that in the case of fat mobilization as in DM, the hyperketonemia and other small organic molecules are both substrates and inducers of CYP2E1 that will lead to non-alcoholic fatty liver disease (Wang et al., 2003, Oh et al., 2012). </plain></SENT>
<SENT sid="115" pm="."><plain>This overexpressed CYP2E1 exhibits a high capacity to produce free radicals that are probably the cause of liver damage and lipid peroxidation in obese T2D patients (Wang et al. </plain></SENT>
<SENT sid="116" pm="."><plain>2003). </plain></SENT>
<SENT sid="117" pm="."><plain>On the other hand, another study has suggested that DM significantly reduced the catalytic activity as well as the protein level of CYP 3A4 (Dostalek et al., 2011). </plain></SENT>
<SENT sid="118" pm="."><plain>The CYP 3A4 is the most expressed CYP in the liver and intestine and may represent about 60% of total all CYP in liver (Dostalek et al., 2011). </plain></SENT>
<SENT sid="119" pm="."><plain>It belongs to the CYP3A subfamily (other members include CYP 3A5, 3A7 and 3A43) that metabolizing more that 50% of currently used medication and some endogenous substrates for instance, cortisol, estradiol, progesterone, and testosterone (Dostalek et al., 2011). </plain></SENT>
<SENT sid="120" pm="."><plain>Members of CYP3A subfamily exhibit a divergent expression pattern, but they have overlapping substrate specificity (Dostalek et al., 2011). </plain></SENT>
<SENT sid="121" pm="."><plain>The reduced activity and decreased expression of CYP 3A4 as in DM would influence the diabetic patients in respect to the biotransformation of drugs that are substrates of CYP3A. </plain></SENT>
<SENT sid="122" pm="."><plain>Moreover, downregulated CYP3A4 would probably decrease the oxidation of testosterone. </plain></SENT>
<SENT sid="123" pm="."><plain>This would reduce the amount of the biologically active form of dihydrotestosterone that is required for the normal growth of the prostate gland (Dostalek et al., 2011). </plain></SENT>
<SENT sid="124" pm="."><plain>The reduced CYP3A4 activity and protein level in diabetic patients may be because of obesity, and elevated pro-inflammatory cytokines (IL-2 and interferon-Î³) (Sunman et al., 2004; Dostalek et al., 2011), noncytokine components and oxidative stress (Dostalek et al., 2011). </plain></SENT>
<SENT sid="125" pm="."><plain>In an experiment conducted in T2D nonobese GotoâKakizaki rats (Oh et al., 2012), it has been shown that hepatic expression of CYP3A2 was increased, whereas, CYP1A2 and CYP3A1 expression was reduced. </plain></SENT>
<SENT sid="126" pm="."><plain>In another experiment conducted in streptozotocin-induced diabetic Sprague-Dawley male rats (Sindhu et al., 2006), it has been reported that the of CYP1B1, CYP2B1, CYP1A2 and CYP2E1 is upregulated in diabetic rats, in contrast to CYP2C11 that was decreased to more than 90% in the diabetic rats. </plain></SENT>
<SENT sid="127" pm="."><plain>Both of the above studies indicated that in diabetes, the CYP expression is in an isoform-specific manner and that this altered expression can partially be treated with insulin (Sindhu et al., 2006, Oh et al., 2012). </plain></SENT>
<SENT sid="128" pm="."><plain>It has also been reported that metformin decreases the expression of CYP1B1 by down regulation of the aryl hydrocarbon receptor (AhR) expression in breast cancer cells (Do et al., 2014). </plain></SENT>
<SENT sid="129" pm="."><plain>This study suggested that metformin could be used against breast cancer cells development. </plain></SENT>
<SENT sid="130" pm="."><plain>Furthermore, It has been reported that CYP2C8*3 (rs10509681), CYP2C9*2 (rs1799853), CYP3A4 (Ile118Val), CYP2C19*2 and CYP1B1*2 (rs1056827) polymorphisms were associated with increased susceptibility to T2D in Indian, Japanese, Mexican and Saudi populations, respectively (Yamada et al., 2007; Hoyo-Vadillo et al., 2010; Mahdi et al., 2016; Elfaki et al., 2018). </plain></SENT>
</text></p></sec><sec id="sec2-8"><title><text><SENT sid="131" pm="."><plain>Roles of CytochromeP450 in Atherosclerosis </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>Arachidonic acid is metabolized by the CYP450 (CYP 2B, 2C8, 2C9, 2C10, 2J2) or arachidonic acid epoxygenase to epoxyeicosatrienoic acids (EETs). </plain></SENT>
<SENT sid="133" pm="."><plain>The EETs act as an endothelium-derived hyperpolarizing factor (EDHF) that functions as vasodilator in all vasculatures including the coronary arteries (Chawengsub et al. </plain></SENT>
<SENT sid="134" pm="."><plain>2009). </plain></SENT>
<SENT sid="135" pm="."><plain>It has been shown in cultured human endothelial cells and native porcine coronary artery endothelial cells that the EDHF metabolite of arachidonic acid by CYP2C is the most vital cause of endothelium relaxation (Fisslthaler et al., 2000). </plain></SENT>
<SENT sid="136" pm="."><plain>Other relaxing factors include prostacyclin (PGI2) and nitric oxide (NO) (Chawengsub et al., 2009). </plain></SENT>
<SENT sid="137" pm="."><plain>These CYP450 enzymes therefore prevent or regress the atherosclerosis (Luoma, 2007). </plain></SENT>
<SENT sid="138" pm="."><plain>On the other hand, reactive oxygen species (ROS) are also generated by CYP2C catalytic reactions (particularly by CYP2C9) in coronary artery endothelial cells (Fleming et al., 2001). </plain></SENT>
<SENT sid="139" pm="."><plain>When the CYP2C is over produced, it will generate more ROS (Ercan et al., 2008). </plain></SENT>
<SENT sid="140" pm="."><plain>The deleterious effects of the ROS include the inhibition of the relaxation mediated by the NO and the elevated activity of the redox-sensitive transcription factor (NF-ÎºB) (Fleming et al., 2001). </plain></SENT>
<SENT sid="141" pm="."><plain>The NF-ÎºB pathway plays important roles in the development of metabolic disease such as atherosclerosis and T2D (Baker et al., 2011). </plain></SENT>
<SENT sid="142" pm="."><plain>NF-ÎºB pathway contributes to the inflammatory response by the production of cytokines, recruitment of WBCs, differentiation of immune cells, and survival of the cells for example the macrophage foam cells, whose necrosis initiated the atherosclerotic plaques (Baker et al., 2011). </plain></SENT>
<SENT sid="143" pm="."><plain>Furthermore, ROS enhances the expression of vascular cell adhesion molecule1 (VCAM-1) (Fleming et al., 2001). </plain></SENT>
<SENT sid="144" pm="."><plain>The role of VCAM-1 in the inflammatory response and atherosclerosis is well established (Skeoch et al., 2014, Denys et al. </plain></SENT>
<SENT sid="145" pm="."><plain>2016). </plain></SENT>
<SENT sid="146" pm="."><plain>Moreover, the CYP1B1 has been shown to promote the generation of ROS and contribute to the development of hyperlipidemia and atherosclerosis in apolipoprotein Eâdeficient mice fed atherogenic diet (Song et al., 2016). </plain></SENT>
<SENT sid="147" pm="."><plain>This study demonstrated that the CYP1B1 inhibitors such as 2,3â,4,5â-tetramethoxystilbene (TMS) can be used for treatment of atherosclerosis (Song et al., 2016). </plain></SENT>
</text></p><p><text><SENT sid="148" pm="."><plain>CYP7A1 plays a protective role against atherosclerosis (Li et al., 2011). </plain></SENT>
<SENT sid="149" pm="."><plain>CYP7A1 (also known as cholesterol 7Î±-hydroxylase) catalyzes the committed step in cholesterol and bile acids synthesis in hepatocytes (Li et al., 2011), and is critical for their homeostasis (Li et al., 2011). </plain></SENT>
<SENT sid="150" pm="."><plain>CYP7A1 maintains this homeostasis by enhancing formation of bile acids from cholesterol, and increases free cholesterol secreted in bile without increasing cholesterol reabsorption by intestinal cells (Li et al., 2011). </plain></SENT>
<SENT sid="151" pm="."><plain>In man, a frame shift mutation in CYP7A1 gene (L413fsX414) that lead to enzyme loss of function would result in hypercholesterolemia and premature coronary and peripheral vascular disease (Pullinger et al., 2002). </plain></SENT>
<SENT sid="152" pm="."><plain>Recently, it has been shown in mice that the overexpression of CYP7A1 attenuates atherosclerosis by increasing secretion of bile, decreasing serum LDL-C, and decreasing acculturation of visceral fat deposits (Krishnamurthy et al., 2016). </plain></SENT>
</text></p><p><text><SENT sid="153" pm="."><plain>CYP4A11 also exerts anti- atherosclerosis effect and metabolize arachidonic acid into the vasoactive 20-hydroxyeicosatetraenoic acid (20-HETE) (Fu et al., 2013; White et al., 2013). </plain></SENT>
<SENT sid="154" pm="."><plain>SNP in the promoter of CYP4A11 (rs9332978 T&gt;C) has been reported to be associated with coronary artery disease in females of Russian cohort (Sirotina et al., 2018). </plain></SENT>
<SENT sid="155" pm="."><plain>This study proposed that the estradiol inhibits expression of CYP4A11 in the carriers of CC genotype which would result in reduced production of the vasoactive 20-HETE (Sirotina et al., 2018). </plain></SENT>
<SENT sid="156" pm="."><plain>Other polymorphism in CYP4A11gene is (T8590C) polymorphism which reduces its catalytic activity (White et al., 2013). </plain></SENT>
<SENT sid="157" pm="."><plain>This polymorphism was associated with a reduced HDL-C level and elevated C-reactive protein concentration in females (White et al., 2013). </plain></SENT>
<SENT sid="158" pm="."><plain>It is suggested that CYP4A11with reduced activity would lead to decreased synthesis of Ï-hydroxylated epoxyeicosatrienoic acids which is an endogenous agonist of peroxisome proliferator-activated receptor-Î± (PPARÎ±) (White et al., 2013). </plain></SENT>
<SENT sid="159" pm="."><plain>PPAR Î± is modulated by estrogen, and its agonist reduces the blood lipids, increases HDL-C and exert anti-inflammatory effect (Cuzzocrea et al., 2006; Nissen et al., 2007; White et al., 2013). </plain></SENT>
</text></p></sec><sec id="sec2-9"><title><text><SENT sid="160" pm="."><plain>Cytochrome P450 Gene Polymorphism </plain></SENT>
</text></title><p><text><SENT sid="161" pm="."><plain>Genetic polymorphisms in CYPs are a major cause of the inter individuals variation in drug metabolism. </plain></SENT>
<SENT sid="162" pm="."><plain>They lead to the occurrence of variation in response to the drugs ranging from adverse effects to lack of efficacy (Ingelman-Sundberg et al., 1999). </plain></SENT>
<SENT sid="163" pm="."><plain>From the 50 identified CYPs isoenzymes that catalyze the drug metabolism, there are more than 20 genes of CYPs are functionally polymorphic, for instance the CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP1B1, and CYP1A2. </plain></SENT>
<SENT sid="164" pm="."><plain>Therefore, about 40% of drug metabolism is catalyzed by the polymorphic CYPs (Bernard et al., 2006). </plain></SENT>
<SENT sid="165" pm="."><plain>Furthermore, polymorphisms of CYPs have been reported to confer diseases susceptibility (Table 2) (Pikuleva and Waterman, 2013; Meng, Ma et al. </plain></SENT>
<SENT sid="166" pm="."><plain>2015, Mittal et al., 2015) as well as disease protection or reduced risk (Silvestri et al., 2003; Yamada et al., 2007; Ur Rasheed et al., 2017). </plain></SENT>
<SENT sid="167" pm="."><plain>In the following paragraphs we discuss some clinically important polymorphic CYPs. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="168" pm="."><plain>Some CYPs with Their Endogenous, Drug Substrates, Inhibitors and Their Capability to Activate Procarcingens </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>CYP Enzyme </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>âEndogenous substrates </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>ââDrug substrates </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>ââInhibitors </plain></SENT>
</text></th><th align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>Importance in Procarcinogen activation </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>1- CYP2D6 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>Hydroxytryptamines, neurosteroids (Wang et al. </plain></SENT>
<SENT sid="176" pm="."><plain>2009) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>Tamoxifen, sparteine, dextromethorphan, debrisoquine (Ferraldeschi et al., 2010, Farooq et al., 2016) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>Bupropion (Kotlyar et al., 2005) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>No (Johansson and Ingelman-Sundberg, 2011) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>2- CYP2A6 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>Retinoid acids, steroids (Di et al., 2009). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>Coumarin, Methoxyflurane, Letrozole (Raunio et al., 2001) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>N1-(4-fluorophenyl) cyclopropane-1-carboxamide, 4-chloroben zylamine, 4-bromobenzylamine, 2-chlorobenzylamine (Rahnasto et al., 2008). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>No (Johansson and Ingelman-Sundberg, 2011). </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>3- CYP2C9 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>steroids, melatonin, retinoids, arachidonic acid (Zhou et al., 2009). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>Angiotensin II blocker, Tamoxifen, Diclofenac, Ibuprofen, Glibenclamide, Glipizide, Warfarin, Tolbutamide, phenytoin (Van Booven et al., 2010) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>Benzbromarone, benzofuran derivatives (Locuson et al., 2003). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>No (Johansson and Ingelman-Sundberg, 2011). </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>4- CYP2C19 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>Estradiol, progesterone, testosterone, estrone (Persson et al., 2014) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>clopidogrel, diazepam, omeprazole, citalopram (Sanford et al. </plain></SENT>
<SENT sid="193" pm="."><plain>2013, Zhou et al., 2013) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>Cannabidiol (Jiang et al., 2013) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>No (Johansson and Ingelman-Sundberg, 2011). </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>5- CYP1B1 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain>Estradiol (Halberg et al., 2008) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>docetaxel, paclitaxel, mitoxantrone and flutamide (McFadyen, et al., 2004). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>Quinazoline derivatives (Mohd Siddique et al., 2017). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>Yes (Halberg et al. </plain></SENT>
<SENT sid="201" pm="."><plain>2008) </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>6- CYP1A2 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>Steroids, retinols, melatonin, arachidonic acids, uroporphyrinogen (Zhou et al. </plain></SENT>
<SENT sid="204" pm="."><plain>2009) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>Paracetamol, theophylline, propranolol, lidocaine (Vasanthanathan et al. </plain></SENT>
<SENT sid="206" pm="."><plain>2009, Zhou et al., 2009) </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>Artemisinin and thiabendazole (Bapiro Sayi et al., 2005). </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>Yes (Ayari et al. </plain></SENT>
<SENT sid="209" pm="."><plain>2013) </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="210" pm="."><plain>Examples of Some Diseases Associated with Cytochrome P450 Enzymes </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain>CYP </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>ââPolymorphism </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>ââDisease </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>ââPopulation </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>ââReference </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>CYP2D6 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>RS3892097 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>Increased risk to Parkinson disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>Pakistan </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>Anwarullah et al., 2017 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>CYP19A1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>rs3751592 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>Alzheimer disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>Chinese </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>Zheng et al., 2016 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>CYP2C9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>rs4918758 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>Reduced risk Coronary heart disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>Russian </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>Polonikov et al., 2017 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>CYP2C9 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>rs9332242 and rs61886769 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>epistatic interactions to Coronary heart disease susceptibility </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>Russian </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>Polonikov et al., 2017 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>CYP1B1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>Wild </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>Atherosclerosis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>mice </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>Song et al., 2016 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>CYP4A11 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>rs1126742rs3890011 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>essential hypertension </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>Chinese </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>Zhang et al., 2017 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>CYP4F2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>rs2108622 and rs3093105 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>Coronary heart disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>Chinese </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain>Yu et al, 2014 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>CYP8A1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>C1117A </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>Left main coronary artery disease </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>Greece </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>Bousoula et al., 2012 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>CYP2J2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="257" pm="."><plain>-50G/T </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain>Ischemic stroke </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>Chinese </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>Wang et al., et al. </plain></SENT>
<SENT sid="261" pm="."><plain>2017 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>CYP1B1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>rs1056827 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>T2D </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain>Saudi </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>Elfaki et al., 2018 </plain></SENT>
</text></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>CYP24A1* </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>rs6068812rs114368325 </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>idiopathic infantile hypercalcemia </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>German, Russia, Turkey </plain></SENT>
</text></td><td align="left" valign="top" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>Schlingmann et al., 2011 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="272" pm="."><plain>CYP7A1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain>rs3808607 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>Tuberculosis </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>Moroccan </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>Qrafli et al 2014 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>CYP1A2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>T3801C at 3âUTR </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>Prostate cancer </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain>Indian </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>Vijayalakshmi et al 2005 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>CYP1A2 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>rs762551 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>Cancers </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>Caucasians </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>Wang et al., 2012 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="287" pm="."><plain>CYP17A1 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="288" pm="."><plain>Wild </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="289" pm="."><plain>Prostate cancer </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="290" pm="."><plain>General </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="291" pm="."><plain>Gomez, et al. </plain></SENT>
<SENT sid="292" pm="."><plain>2015 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="293" pm="."><plain>CYP17 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="294" pm="."><plain>rs743572 </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="295" pm="."><plain>Gallbladder cancer /breast cancer </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="296" pm="."><plain>Indian (Tobacco users)/Chinese </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="297" pm="."><plain>Sun et al. </plain></SENT>
<SENT sid="298" pm="."><plain>2018 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="t2f1"><label>*</label><p><text><SENT sid="299" pm="."><plain>CYP24A1 catalyzed the catabolism of the 1, 25-dihydroxyvitamin D. </plain></SENT>
<SENT sid="300" pm="."><plain>Failure of 1, 25-dihydroxyvitamin degradation leads to elevated calcium in the blood and vomiting, loss of fluids, and nephrocalcinosis (Schlingmann et al., 2011). </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="sec2-10"><title><text><SENT sid="301" pm="."><plain>a. </plain></SENT>
<SENT sid="302" pm="."><plain>Cytochrome P450 2D6 (CYP2D6) </plain></SENT>
</text></title><p><text><SENT sid="303" pm="."><plain>The CYP 2D6 represents a small percentage of all hepatic cytochrome P 450s (Ingelman-Sundberg, 2005). </plain></SENT>
<SENT sid="304" pm="."><plain>It is encoded by the CYP2D6 gene that is localized on chromosome 22q13.1, and catalyzes the biotransformation of about 20-25% of the clinically used drugs (Ingelman-Sundberg, 2005). </plain></SENT>
<SENT sid="305" pm="."><plain>The endogenous substrates of CYP2D6 include neurotransmitters and neurosteroids, for examples, the serotonin, or hydroxytryptamines, 5-methoxyindolethylamine O-demethylase, and pinoline, progesterone and Hydroxyprogesterone (Wang et al., 2014). </plain></SENT>
<SENT sid="306" pm="."><plain>The crystal structure of human CYP 2D6 at a resolution of 3.0 Ã has been described (Rowland et al., 2006). </plain></SENT>
<SENT sid="307" pm="."><plain>The CYP2D6 fold similarly to the characteristic P450 fold as for all CYP family member, with lengths and orientations of the alpha helices and sheets very similar to CYP 2C9 (Rowland et al., 2006). </plain></SENT>
<SENT sid="308" pm="."><plain>The most important difference is that the F helix, the F-G loop, the Bâ helix, Î² sheet 4, and part of Î² sheet 1 are found on the distal face of CYP2D6 (Rowland et al., 2006). </plain></SENT>
<SENT sid="309" pm="."><plain>The CYP 2D6 enzyme has a well-defined active site cavity above the heme group (Figure 1A). </plain></SENT>
<SENT sid="310" pm="."><plain>The active site was described as having the shape of a right foot (Rowland et al., 2006). </plain></SENT>
<SENT sid="311" pm="."><plain>The polymorphism of the enzyme results in poor, intermediate, efficient or ultra-rapid metabolizers (UMs) of CYP2D6 drugs substrates (Ingelman-Sundberg, 2005). </plain></SENT>
<SENT sid="312" pm="."><plain>The drug substrate include antidepressants, neuroleptics, some antiarrhythmics, lipophilic Î²-adrenoceptor blockers and opioids (Bertilsson et al., 2002). </plain></SENT>
<SENT sid="313" pm="."><plain>Some individuals carry nonfunctional gene copies of the CYP2D6 in which there is one or more nucleotide is changed. </plain></SENT>
<SENT sid="314" pm="."><plain>This mutated gene results in faulty mRNA, which is translated to incomplete proteins (Yu et al., 2002). </plain></SENT>
<SENT sid="315" pm="."><plain>The incomplete protein is unable to bind the heme. </plain></SENT>
<SENT sid="316" pm="."><plain>This result in enzyme has no catalytic activity. </plain></SENT>
<SENT sid="317" pm="."><plain>Some CYP2D6 alleles contain insertion or deletion mutations resulting in one or more change in amino acid residues (Yu et al., 2002). </plain></SENT>
<SENT sid="318" pm="."><plain>For example, the variant allele CYP2D6*17 result from the mutations Thr107Iso, Arg296Cys, and Ser486Thr. </plain></SENT>
<SENT sid="319" pm="."><plain>These mutations lead to a CYP2D6 with reduced catalytic activity (Ingelman-Sundberg., 2005). </plain></SENT>
<SENT sid="320" pm="."><plain>Also the CYP2D6*4 that result from a defective splicing and produce an inactive verstion CYP2D6 (Ingelman-Sundberg 2005). </plain></SENT>
<SENT sid="321" pm="."><plain>These changes may result in the structural change or misfolded protein that will have a reduced or no catalytic activity (Yu et al., 2002). </plain></SENT>
<SENT sid="322" pm="."><plain>This variation produces different phenotypes of the 2D6.1 (wild types), for example the 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms (Yu et al., 2002). </plain></SENT>
<SENT sid="323" pm="."><plain>The catalytic activities of these CYP2D6 phenotypes in comparison to the wild type 2D6.1, decrease in the order 2D6.2 &gt; 2D6.17 &gt; 2D6.10 (Yu et al., 2002). </plain></SENT>
<SENT sid="324" pm="."><plain>The (CYP2D6) ultra-rapid metabolizer has been reported to be protected against Parkinson disease, whereas, the poor metabolizer is being susceptible (Ur Rasheed et al., 2017). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="325" pm="."><plain>The Three Dimensional Structures (3D) of Cytochromes P450 Enzymes in Ribbon Representations, A- The secondary structure (PDB ID, 2F9Q) of CYP2D6 has a well-defined binding pocket above the heme group containing amino acid (illustrated in green and surface structure) residues that are implicated in recognition and binding of substrate (Asp-301, Glu-216, Phe-483, and Phe-120) [95]. </plain></SENT>
<SENT sid="326" pm="."><plain>B- The secondary structure of CYP2A6 (PDB 3T3Q). </plain></SENT>
<SENT sid="327" pm="."><plain>The amino acid forming the active site is indicated in surface structure and green color (Phe 300, Ala 301, Ser208, Ser369 and Leu370). </plain></SENT>
<SENT sid="328" pm="."><plain>C- The secondary structure of P450 2C9 (PDB ID, 1R9O). </plain></SENT>
<SENT sid="329" pm="."><plain>The sites of two important mutations are shown in surface structure and green color (R144C and 359I&gt;L). </plain></SENT>
<SENT sid="330" pm="."><plain>D- The secondary structure of CYP2C19 (PDB code ID, 4GQS). </plain></SENT>
<SENT sid="331" pm="."><plain>The site of SNP that results in alteration of the amino acid residue R442C is illustrated in surface structure and green color. </plain></SENT>
<SENT sid="332" pm="."><plain>E. the secondary structure of CYP1B1 (PDB ID, 3PM0). </plain></SENT>
<SENT sid="333" pm="."><plain>There are two important single nucleotide variations in CYP1B1 gene in A119S and L432V that resulted in disease phenotypes. </plain></SENT>
<SENT sid="334" pm="."><plain>The heme molecule is not shown. </plain></SENT>
<SENT sid="335" pm="."><plain>This figure has been prepared using YASARA View (version 17.7.30). </plain></SENT>
</text></p></caption><graphic xlink:href="APJCP-19-2057-g001"/></fig></SecTag></sec><sec id="sec2-11"><title><text><SENT sid="336" pm="."><plain>b. </plain></SENT>
<SENT sid="337" pm="."><plain>The Cytochrome P450 2A6 (CYP2A6) </plain></SENT>
</text></title><p><text><SENT sid="338" pm="."><plain>The CYP2A6 enzyme participates in the biotransformation of several xenobiotics that has been categorized as pharmaceuticals and toxic agents (Raunio et al., 2001). </plain></SENT>
<SENT sid="339" pm="."><plain>Examples of drugs substrates of CYP2A6 include Coumarin, Methoxyfurane, Halothane, Valproic acid, whereas, the toxic substrates of the CYP2A6 include the Nicotine, Quinoline and methyl tertbutyl ether (Raunio et al., 2001). </plain></SENT>
<SENT sid="340" pm="."><plain>Inhibitors of the CYP2A6 include methoxsalen (8-methoxypsoralen), menthofuran, pilocarpine and the monoamine oxidase inhibitor tranylcypromine (Yano et al., 2005). </plain></SENT>
<SENT sid="341" pm="."><plain>The inhibition of the CYP2A6 has two important aspects. </plain></SENT>
<SENT sid="342" pm="."><plain>Firstly, its inhibitor the methoxsalen (8-methoxypsoralen) reduces nicotine metabolism, and hence methoxsalen have been suggested as a novel approach for smoking cessation (Bagdas et al., 2014). </plain></SENT>
<SENT sid="343" pm="."><plain>Secondly, inhibition of CYP 2A6 inhibited the formation tobacco-specific carcinogens Nâ-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to mutagenic compounds in human liver microsomes (Patten et al., 1997, Yano et al., 2005). </plain></SENT>
<SENT sid="344" pm="."><plain>The crystal structure of the CYP2A6 complexed with coumarin and methoxsalen was determined (Yano et al., 2005). </plain></SENT>
<SENT sid="345" pm="."><plain>The CYP2A6 crystal structure revealed that the CYP2A6 catalytic domain fold in 16 alpha helices and 4 beta sheets like all mammalian microsomal CYPs. </plain></SENT>
<SENT sid="346" pm="."><plain>However, its binding pocket is hydrophobic, compact and represent about one quarter of the binding pockets of some important drug-metabolizing CYPs like CYPs 2C8 (PDB code 1PQ2), 2C9 (PDB code 1R9O) and 3A4 (PDB code 1TQN)(Yano et al., 2005). </plain></SENT>
<SENT sid="347" pm="."><plain>Site-directed mutagenesis and homology modeling studies have indicated that the amino acids residues (e.g. Phe300, Ala 301, Ser 208 red, Ser369, and Leu370) may play have a key role in recognition of substrates, Figure 1 (Di et al., 2009). </plain></SENT>
</text></p><p><text><SENT sid="348" pm="."><plain>CYP2A6 gene polymorphism has been associated with smoking behavior, drug metabolism and lung cancer risk (Di et al., 2009). </plain></SENT>
<SENT sid="349" pm="."><plain>This polymorphism resulted in a variety of phenotypes of the CYP2A6. </plain></SENT>
<SENT sid="350" pm="."><plain>These phenotypes are wild type CYP2A6*1A with normal enzyme activity (Hukkanen et al., 2005; Akrodou, 2015). </plain></SENT>
<SENT sid="351" pm="."><plain>The phenotypes CYP2A6*4A, CYP2A6*4B, and CYP2A6*4D have no enzyme activity due to the whole gene deletion (Hukkanen et al., 2005), or due to single nucleotide substitution (CYP2A6*2). </plain></SENT>
<SENT sid="352" pm="."><plain>There is also the allele CYP2A6*5 that encoded a very unstable enzyme with no catalytic activity because the conserved Glycin-479 has been substituted with the valine (Oscarson et al., 1999). </plain></SENT>
<SENT sid="353" pm="."><plain>The CYP2A6 is able to activate several procarcinogens such as nitrosamines and the aflatoxins. </plain></SENT>
<SENT sid="354" pm="."><plain>Logically, the phenotypes that are without enzyme activity (CYP2A6*4A, CYP2A6*4B, and CYP2A6*4D) are protected from the cancers caused by the procarcinogens that are substrates of CYP2A6 (Raunio et al., 2001). </plain></SENT>
</text></p></sec><sec id="sec2-12"><title><text><SENT sid="355" pm="."><plain>c. </plain></SENT>
<SENT sid="356" pm="."><plain>The Cytochrome P450 2C9 (CYP2C9) </plain></SENT>
</text></title><p><text><SENT sid="357" pm="."><plain>CYP2C9 plays a major role in phase I metabolism of xenobiotic and some endogenous compounds (Van Booven et al., 2010). </plain></SENT>
<SENT sid="358" pm="."><plain>CYP2C9 is the second main CYP expressed in hepatocytes, whereas the CYP3A4 is most expressed CYP in liver cells (Van Booven et al., 2010). </plain></SENT>
<SENT sid="359" pm="."><plain>The CYP2C9 is the drug-metabolizing enzyme for about 15-20% of all drugs undergoing phase I metabolism. </plain></SENT>
<SENT sid="360" pm="."><plain>For instance, the nonsteroidal anti-inflammatories, oral anticoagulants, and oral hypoglycemic (Rettie and Jones, 2005). </plain></SENT>
<SENT sid="361" pm="."><plain>It has been shown that CYP2C9 is induced by treatment with rifampicin (Van Booven et al., 2010). </plain></SENT>
<SENT sid="362" pm="."><plain>The metabolic rates of P450 2C9 substrates for examples the phenytoin, tolbutamide, S-warfarin, losartan are increased to about two times in patients treated with rifampicin (Kanebratt et al., 2008). </plain></SENT>
<SENT sid="363" pm="."><plain>Inhibitors of the CYP2C9 include amiodarone, fluconazole, and sulphaphenazole (Miners and Birkett, 1998; Van Booven et al., 2010). </plain></SENT>
<SENT sid="364" pm="."><plain>The crystal structure of the human CYP2C9 unliganded and bound to the anti-coagulant drug warfarin has been elucidated (Williams et al., 2003). </plain></SENT>
<SENT sid="365" pm="."><plain>The crystal structure (Protein Data Bank ID: 1OG2 and 1OG5) revealed a novel binding pocket in CYP2C9 and unexpected interactions between the CYP2C9 and the drug Warfarin (Williams et al., 2003). </plain></SENT>
<SENT sid="366" pm="."><plain>The presence of this novel binding pocket suggests CYP2C9 may binds multiple ligands and undergo allosteric mechanism during its biological function (Williams et al., 2003). </plain></SENT>
<SENT sid="367" pm="."><plain>The crystal structure of CYP2C9 in complex with NSAID flurbiprofen has also been elucidated (Protein Data Bank ID: 1R9O) (Wester et al., 2004). </plain></SENT>
<SENT sid="368" pm="."><plain>It has revealed that the residue Arginine 108 is responsible for the binding of flurbiprofen and other substrates like naproxen, ibuprofen, diclofenac to CYP2C9 (Wester et al., 2004). </plain></SENT>
<SENT sid="369" pm="."><plain>Two residues of on helix I (Aspartate 293 and Asparagine 289) are interacting and stabilizing Arginine 108 (Wester et al., 2004). </plain></SENT>
<SENT sid="370" pm="."><plain>Polymorphism of CYP2C9 has been associated with adverse drug events (Van Booven et al., 2010). </plain></SENT>
<SENT sid="371" pm="."><plain>Individuals with low CYP2C9 catalytic activity develops adverse drug reactions particularly with substrates with a narrow therapeutic index, for instance, S-warfarin, phenytoin, glipizide, and tolbutamide (Pirmohamed and Park, 2003). </plain></SENT>
<SENT sid="372" pm="."><plain>Examples of two important mutations in CYP2C9 are the CYP2C9 (Arg144Cys, rs1799853 and Iso359Leu, rs1057910 Figure 1C) that result in CYP2C9 poor metabolic activities (Van Booven et al., 2010). </plain></SENT>
<SENT sid="373" pm="."><plain>These two mutations are significantly highly frequent in Caucasian populations than in African and Asian populations (Sistonen et al., 2009, Van Booven et al., 2010). </plain></SENT>
<SENT sid="374" pm="."><plain>When treated with anti-coagulant warfarin, the patients with these two mutations have prolonged clotting time as well as an elevated possibility of severe bleeding complications (Aithal et al., 1999). </plain></SENT>
<SENT sid="375" pm="."><plain>In treatment with the hypoglycemic agent, glipizide and tolbutamide, these patients (with Arg144Cys, rs1799853 and Iso359Leu, rs1057910 mutations) may develop very low blood glucose levels (Kidd et al., 1999). </plain></SENT>
<SENT sid="376" pm="."><plain>Moreover, these individuals develop symptoms of phenytoin overdose when treated with it (Ninomiya et al. </plain></SENT>
<SENT sid="377" pm="."><plain>2000), since they are poor metabolizers of these drugs. </plain></SENT>
<SENT sid="378" pm="."><plain>Furthermore, recently, it has been reported that patients taking long-term oral anti-coagulants treatment with Vitamin K antagonists are at a high risk of thrombotic and/or major hemorrhage adverse events if they are carriers of one of three polymorphisms (Misasi et al., 2016), and the (Iso359Leu rs1057910) is one of them (Misasi et al., 2016). </plain></SENT>
<SENT sid="379" pm="."><plain>The sulphonylureas are antidiabetic medications. </plain></SENT>
<SENT sid="380" pm="."><plain>They stimulate insulin secretion from the Pancreatic Beta cells (Rendell, 2004). </plain></SENT>
<SENT sid="381" pm="."><plain>Sulphonylureas bind the ATP-sensitive potassium channel. </plain></SENT>
<SENT sid="382" pm="."><plain>This binding closes the potassium channel and open the calcium channel which results in insulin secretion from pancreatic Beta cells (Rendell, 2004). </plain></SENT>
<SENT sid="383" pm="."><plain>Sulphonylureas are metabolized by CYP2C9 in hepatocytes. </plain></SENT>
<SENT sid="384" pm="."><plain>Therefore, CYP2C9 gene variations might be associated with risk of diabetes and/or altered drug reaction to the Sulphonylureas (Pollastro et al., 2015). </plain></SENT>
<SENT sid="385" pm="."><plain>It has been shown that CYP2C9 (Iso359Leu rs1057910) polymorphism is associated with a more reduction of fasting blood glucose level and a higher rate of treatment response to gliclazide (Zeng et al., 2016). </plain></SENT>
</text></p></sec><sec id="sec2-13"><title><text><SENT sid="386" pm="."><plain>d. </plain></SENT>
<SENT sid="387" pm="."><plain>Cytochrome P450 2C19 (CYP2C19) </plain></SENT>
</text></title><p><text><SENT sid="388" pm="."><plain>The Cytochrome P450 2C19 is encoded by chromosome 10, and is expressed in the human liver (Uehara et al., 2015). </plain></SENT>
<SENT sid="389" pm="."><plain>It is the most polymorphic member of CYP2 C subfamily (Lee, 2012). </plain></SENT>
<SENT sid="390" pm="."><plain>It catalyzes the metabolism of drugs for example the S-mephenytoin, omeprazole, in addition to some of antidepressants and serotonin reuptake inhibitors (Reynald et al., 2012). </plain></SENT>
<SENT sid="391" pm="."><plain>Genetic polymorphism in CYP2C19 results in inter-individual differences in the enzyme expression and in metabolic activity. </plain></SENT>
<SENT sid="392" pm="."><plain>The Allelic variation (gene polymorphism) classified the population according to the catalytic activity of CYP2C19 to poor, extensive and ultra-rapid phenotypes for drug clearance (Reynald et al., 2012). </plain></SENT>
<SENT sid="393" pm="."><plain>For instance, the individuals who are carriers of the loss-of-function alleles of CYP2C19 have shown to have a decreased antiplatelet effect of clopidogrel as well as lower blood concentrations of the active form of clopidogrel (Brandt et al., 2007; Simon et al., 2009). </plain></SENT>
<SENT sid="394" pm="."><plain>This is since the clopidogrel (pro-drug) should be sufficiently metabolized by the CYP2C19 such that it is converted to an effective inhibitor of platelet aggregation (Dean, 2012). </plain></SENT>
<SENT sid="395" pm="."><plain>It is therefore, the patients that are homozygous for the CYP2C19 loss-of-function alleles develop adverse clinical reactions when treated with clopidogrel after acute myocardial infarction (Simon et al., 2009). </plain></SENT>
<SENT sid="396" pm="."><plain>On the other hand, the individuals that are ultrarapid metabolizers with the CYP2C19*17 allele can exhibit a good therapeutic response that is associated with an increased effect of clopidogrel and probably an increased bleeding risk (Sibbing et al., 2010, Tiroch et al., 2010). </plain></SENT>
<SENT sid="397" pm="."><plain>Moreover, it has been reported the SNP (168946C&gt;T) in exon 9 of CYP2C19 gene would lead to change in arginine 442 to cysteine (Morita et al., 2004). </plain></SENT>
<SENT sid="398" pm="."><plain>This change from a positively-charged amino acid arginine 442 to the sulphur-containing amino acid cysteine is located proximal to the CYP2C19 heme binding region (Figure 1 D) and reduces it catalytic activity (Morita et al. </plain></SENT>
<SENT sid="399" pm="."><plain>2004). </plain></SENT>
<SENT sid="400" pm="."><plain>The crystal structure of CYP2C19 complexed with the inhibitor inhibitor (2-methyl-1-benzofuran-3-yl)-(4- hydroxy-3,5-dimethylphenyl) methanone was to 2.87 Ã resolution by x-ray crystallography(Reynald, Sansen et al. </plain></SENT>
<SENT sid="401" pm="."><plain>2012). </plain></SENT>
<SENT sid="402" pm="."><plain>The 3D structure of CYP2C19 is highly similar to that of CYP2C9 and CYP2C8. </plain></SENT>
<SENT sid="403" pm="."><plain>However, its binding pockets are completely different in term of topography, polarity and hydrophobicity since the amino acid residues are divergent in this region which may explain why these enzymes exhibit different substrate/inhibitor specificities (Reynald et al., 2012). </plain></SENT>
</text></p></sec><sec id="sec2-14"><title><text><SENT sid="404" pm="."><plain>e. </plain></SENT>
<SENT sid="405" pm="."><plain>Cytochrome P450 1B1 (CYP1B1) </plain></SENT>
</text></title><p><text><SENT sid="406" pm="."><plain>The cytochrome P450 1B1 (CYP1B1) catalyzes the metabolism of number of xenobiotic such as theophylline, ethoxyresorufin, and caffeine (Rochat et al., 2001; Zanger and Schwab, 2013). </plain></SENT>
<SENT sid="407" pm="."><plain>It also activates some procarcinogens, for instance, heterocyclic amines, polycyclic hydrocarbons, aromatic amines, and nitropolycyclic hydrocarbons (Chun and Kim, 2016). </plain></SENT>
<SENT sid="408" pm="."><plain>It is encoded by the CYP1B1 gene that is regulated by the AHR (Nebert et al., 2004), and other transcription factors such as AHR nuclear translocator (ARNT) complex (AHR/ARNT), the Sp1 transcription factor, a cyclic AMP (cAMP)âresponse elementâbinding protein (CREB), and the estrogen receptor (Sissung et al., 2006). </plain></SENT>
<SENT sid="409" pm="."><plain>The crystal structure of the CYP1B1 was determined (Wang et al., 2011), it has a narrow slot-like active site that is similar to that of CYP1A1, however, the residues around the edge of the active sites are different for specific binding of substrates and inhibitors (Wang et al., 2011). </plain></SENT>
<SENT sid="410" pm="."><plain>Using the reverse transcriptase-coupled PCR, CYP1B1 mRNA was detected in hepatocytes, lymphocytes, and uterus (Hakkola et al., 1997). </plain></SENT>
<SENT sid="411" pm="."><plain>CYP1B1 gene is expressed in different amounts among tissues, the highest mRNA expression levels were found in extrahepatic tissues such as renal, uterine, heart, brain, lung, skeletal muscle (Pavek and Dvorak, 2008). </plain></SENT>
<SENT sid="412" pm="."><plain>CYP1B1 is highly expressed in estrogen related organ such as uterus, ovaries and mammary glands (Tsuchiya et al, 2004). </plain></SENT>
<SENT sid="413" pm="."><plain>The CYP1B1 catalyzes the metabolism of endogenous substrates such as 17 Î²-estradiol into reactive metabolites, such as 4-hydroxyestradiol (Smerdova et al., 2014). </plain></SENT>
<SENT sid="414" pm="."><plain>The 4-hydroxyestradiol, a catechol metabolite reduces the activity of estrogen. </plain></SENT>
<SENT sid="415" pm="."><plain>However, it generates free radicals from the reductive-oxidative cycling with the corresponding quinone and semiquinone forms, which cause cellular damage. </plain></SENT>
<SENT sid="416" pm="."><plain>Therefore, 4-hydroxyestradiol is toxicologically active and may have a role in induction of cancer (Bolton and Thatcher, 2008). </plain></SENT>
<SENT sid="417" pm="."><plain>The 4-hydroxyestradiol level is elevated in human uterine and breast cancers in comparison to normal tissue (Bolton and Thatcher, 2008). </plain></SENT>
<SENT sid="418" pm="."><plain>Mutations in CYP1B1 were reported to be causes of disease phenotype such as the primary congenital glaucoma (Badeeb et al., 2014). </plain></SENT>
<SENT sid="419" pm="."><plain>Moreover, CYP1B1 gene polymorphisms L432V and A119S (rs1056827) were reported to be risk of developing endometrial (Zhu et al., 2011), laryngeal cancers and T2D (Yu et al., 2015; Elfaki et al., 2018). </plain></SENT>
</text></p></sec><sec id="sec2-15"><title><text><SENT sid="420" pm="."><plain>f. </plain></SENT>
<SENT sid="421" pm="."><plain>Cytochrome P450 1A2 (CYP1A2) </plain></SENT>
</text></title><p><text><SENT sid="422" pm="."><plain>CYP1A2 is primarily expressed in hepatocytes and is about 13% of all CYP 450s in liver (Ren et al., 2016). </plain></SENT>
<SENT sid="423" pm="."><plain>About 5% of currently used drugs are metabolized by CYP1A2 (Zhou et al., 2009). </plain></SENT>
<SENT sid="424" pm="."><plain>Drug substrates of CYP1A2 include acetaminophen, paracetamol, theophylline, propranolol, lidocaine, tacrine and triamterene (Vasanthanathan et al., 2009; Zhou et al., 2009). </plain></SENT>
<SENT sid="425" pm="."><plain>Endogenous substrates of CYP1A2 are steroids, retinols, melatonin, uroporphyrinogen, and arachidonic acids (Zhou et al., 2009). </plain></SENT>
<SENT sid="426" pm="."><plain>CYP1A2 is also able to activate procarcinogens (Ayari et al. </plain></SENT>
<SENT sid="427" pm="."><plain>2013). </plain></SENT>
<SENT sid="428" pm="."><plain>Examples of CYP1A2 inducers include tobacco, flutamide, and caffeine (Wang et al., 2005). </plain></SENT>
<SENT sid="429" pm="."><plain>The crystal structure reveal the CYP1A2 folds as the general CYP structure into 4 Beta sheets designated from 1-4, and 12 alpha helices designated from A-L, in addition to several other alpha helices designated by prime or double prime (Sansen et al., 2007). </plain></SENT>
<SENT sid="430" pm="."><plain>The substrate binding pocket of CYP1A2 is narrow, compact and closed to fit binding and oxidation of relatively large and planar substrates such as PAHs (Sansen et al., 2007). </plain></SENT>
<SENT sid="431" pm="."><plain>It has been reported that there is a SNP C&gt;A (rs762551) in intron 1 of CYP1A2 with AA homozygote carriers metabolize the caffeine at highest rate (Womack et al., 2012). </plain></SENT>
<SENT sid="432" pm="."><plain>This polymorphism influences the inducibility of CYP1A2 particularly in smokers (Koonrungsesomboon et al. </plain></SENT>
<SENT sid="433" pm="."><plain>2017). </plain></SENT>
<SENT sid="434" pm="."><plain>The highest CYP1A2 induction rate was reported in AA genotype and no difference between AC and CC genotypes (Sachse et al., 1999). </plain></SENT>
<SENT sid="435" pm="."><plain>It was postulated that the differences in CYP1A2 expression levels are due altered regulatory proteins binding or due to linkage disequilibrium with other mutations influencing inducibility of CYP1A2 (Cornelis et al., 2004). </plain></SENT>
<SENT sid="436" pm="."><plain>It was reported that carriers of CYP1A2 with high activity were at more risk to lung cancer (Seow et al., 2001; Bu, et al. </plain></SENT>
<SENT sid="437" pm="."><plain>2014), confirming the role of CYP1A2 in activating heterocyclic arylamines. </plain></SENT>
<SENT sid="438" pm="."><plain>Furthermore, Cornelis et al reported that individuals had low inducibility CYP1A2 were more susceptible to myocardial infarction (MI) than those had high inducibility CYP1A2 (Cornelis et al., 2004). </plain></SENT>
<SENT sid="439" pm="."><plain>It has been proposed that this increased susceptibility was because MI patients who had low inducibility CYP1A2 had increased cytokines levels (Cornelis et al., 2004). </plain></SENT>
<SENT sid="440" pm="."><plain>The role of cytokines in the pathogenesis of coronary heart disease is well-established (Tousoulis et al., 2016). </plain></SENT>
<SENT sid="441" pm="."><plain>CYP1A2 also metabolizes 17Î²-estradiol to 2-hydroxyestradiol which is then converted to 2-methoxyestradiol by catechol-O-methyltransferase (Ren et al., 2016). </plain></SENT>
<SENT sid="442" pm="."><plain>The 2-methoxyestradiol inhibits hepatocellular carcinoma (HCC) cells proliferation by inducing apoptosis (Ren et al., 2016). </plain></SENT>
<SENT sid="443" pm="."><plain>This study suggested that CYP1A2 downregualtion would result in progression of HCC. </plain></SENT>
</text></p></sec><sec id="sec2-16"><title><text><SENT sid="444" pm="."><plain>Concluding Remarks </plain></SENT>
</text></title><p><text><SENT sid="445" pm="."><plain>Cytochrome 450 (CYP450) is a large superfamily comprised of 18 families. </plain></SENT>
<SENT sid="446" pm="."><plain>There are 57 genes encoding these hemoprotein enzymes. </plain></SENT>
<SENT sid="447" pm="."><plain>CYP540s catalyze various vital reactions. </plain></SENT>
<SENT sid="448" pm="."><plain>They present in mitochondria and endoplasmic reticulum of different tissues, but mainly in hepatocytes and intestinal cells. </plain></SENT>
<SENT sid="449" pm="."><plain>CYP450 are involved in the metabolism of certain endogenous substrate such as cholesterol, estrogen, vitamin D and arachidonic acid. </plain></SENT>
<SENT sid="450" pm="."><plain>They are also catalyzing phase 1 in metabolism of xenobiotics such as drugs and carcinogens. </plain></SENT>
<SENT sid="451" pm="."><plain>Some CYP450 isoforms can activate procarcinogens to the ultimate carcinogens, for example CYP1A1, CYP1A2 and CYP1B1. </plain></SENT>
<SENT sid="452" pm="."><plain>Polymorphisms have been reported in CYP450s genes and cause no or altered enzyme activity. </plain></SENT>
<SENT sid="453" pm="."><plain>These CYP450 gene polymorphisms have been associated with unexpected drug responses as well as susceptibility to diseases such as cancers, type 2 diabetes, and atherosclerosis. </plain></SENT>
</text></p></sec><sec id="sec2-17"><title><text><SENT sid="454" pm="."><plain>Competing interests </plain></SENT>
</text></title><p><text><SENT sid="455" pm="."><plain>The authors declare that they have no competing interests. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="456" pm="."><plain>This project is funded by the Deanship of Scientific research, university of Tabuk grant for project number (No.0178-1437-S) for IE and FMA, and grant number (No.0121-1439-S) for IE. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="ref1"><text><SENT sid="457" pm="."><plain>1AithalGPDayCPKestevenPJDalyAKAssociation of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsLancet1999353717910073515 </plain></SENT>
</text></ref><ref id="ref2"><text><SENT sid="458" pm="."><plain>2AkrodouYMCYP2A6 polymorphisms may strengthen individualized treatment for nicotine dependenceScientifica (Cairo)2015201549151426060595 </plain></SENT>
</text></ref><ref id="ref3"><text><SENT sid="459" pm="."><plain>3Anwarullah AslamMBadshahMAbbasiRFurther evidence for the association of CYP2D6*4 gene polymorphism with Parkinson's disease: a case control studyGenes Environ20173018 </plain></SENT>
</text></ref><ref id="ref4"><text><SENT sid="460" pm="."><plain>4AyariIFedeliUSaguemSRole of CYP1A2 polymorphisms in breast cancer risk in womenMol Med Rep20137280623128882 </plain></SENT>
</text></ref><ref id="ref5"><text><SENT sid="461" pm="."><plain>5BadeebOMMichealSKoenekoopRKden HollanderAIHedrawiMTCYP1B1 mutations in patients with primary congenital glaucoma from Saudi ArabiaBMC Med Genet20141510925261878 </plain></SENT>
</text></ref><ref id="ref6"><text><SENT sid="462" pm="."><plain>6BagdasDMuldoonPPZhuAZTyndaleRFDamajMIEffects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in miceNeuropharmacology201485677224859605 </plain></SENT>
</text></ref><ref id="ref7"><text><SENT sid="463" pm="."><plain>7BakerRGHaydenMSGhoshSNF-kappaB, inflammation, and metabolic diseaseCell Metab201113112221195345 </plain></SENT>
</text></ref><ref id="ref8"><text><SENT sid="464" pm="."><plain>8BapiroTESayiJHaslerJAArtemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humansEur J Clin Pharmacol2005617556116261361 </plain></SENT>
</text></ref><ref id="ref9"><text><SENT sid="465" pm="."><plain>9BernardSNevilleKANguyenATFlockhartDAInterethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implicationsOncologist2006111263516476833 </plain></SENT>
</text></ref><ref id="ref10"><text><SENT sid="466" pm="."><plain>10BertilssonLDahlMLDalenPAl-ShurbajiAMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsBr J Clin Pharmacol2002531112211851634 </plain></SENT>
</text></ref><ref id="ref11"><text><SENT sid="467" pm="."><plain>11BoltonJLThatcherGRPotential mechanisms of estrogen quinone carcinogenesisChem Res Toxicol2008219310118052105 </plain></SENT>
</text></ref><ref id="ref12"><text><SENT sid="468" pm="."><plain>12BousoulaEKolovouVVasiliadisICYP8A1 gene polymorphisms and left main coronary artery diseaseAngiology201263461522072641 </plain></SENT>
</text></ref><ref id="ref13"><text><SENT sid="469" pm="."><plain>13BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost2007524293617900275 </plain></SENT>
</text></ref><ref id="ref14"><text><SENT sid="470" pm="."><plain>14BuZBYeMChengYWuWZFour polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene and lung cancer risk: a meta-analysisAsian Pac J Cancer Prev2014155673925081684 </plain></SENT>
</text></ref><ref id="ref15"><text><SENT sid="471" pm="."><plain>15ChakrabortySGantiAKMarrABatraSKLung cancer in women: role of estrogensExpert Rev Respir Med201045091820658912 </plain></SENT>
</text></ref><ref id="ref16"><text><SENT sid="472" pm="."><plain>16ChangGWKamPCThe physiological and pharmacological roles of cytochrome P450 isoenzymesAnaesthesia199954425010209369 </plain></SENT>
</text></ref><ref id="ref17"><text><SENT sid="473" pm="."><plain>17ChawengsubYGauthierKMCampbellWBRole of arachidonic acid lipoxygenase metabolites in the regulation of vascular toneAm J Physiol Heart Circ Physiol2009297H49550719525377 </plain></SENT>
</text></ref><ref id="ref18"><text><SENT sid="474" pm="."><plain>18ChenTC25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostateAnticancer Res2008282015718649741 </plain></SENT>
</text></ref><ref id="ref19"><text><SENT sid="475" pm="."><plain>19ChenTCSakakiTYamamotoKKittakaAThe roles of cytochrome P450 enzymes in prostate cancer development and treatmentAnticancer Res201232291822213318 </plain></SENT>
</text></ref><ref id="ref20"><text><SENT sid="476" pm="."><plain>20ChuangYTFangLWLin-FengMHChenRHLaiMZThe tumor suppressor death-associated protein kinase targets to TCR-stimulated NF-kappa B activationJ Immunol200818032384918292548 </plain></SENT>
</text></ref><ref id="ref21"><text><SENT sid="477" pm="."><plain>21ChunYJKimDCancer activation and polymorphisms of human cytochrome P450 1B1Toxicol Res201632899327123158 </plain></SENT>
</text></ref><ref id="ref22"><text><SENT sid="478" pm="."><plain>22CornelisMCEl-SohemyACamposHGenetic polymorphism of CYP1A2 increases the risk of myocardial infarctionJ Med Genet2004417586215466009 </plain></SENT>
</text></ref><ref id="ref23"><text><SENT sid="479" pm="."><plain>23CuzzocreaSMazzonEDi PaolaRThe role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammationJ Leukoc Biol200679999101016501055 </plain></SENT>
</text></ref><ref id="ref24"><text><SENT sid="480" pm="."><plain>24DeanLPrattVMcLeodHDeanLClopidogrel therapy and CYP2C19 genotypeMedical genetics summaries [Internet]2012Bethesda MDNational Center for Biotechnology Information(US) </plain></SENT>
</text></ref><ref id="ref25"><text><SENT sid="481" pm="."><plain>25DenysAClavelGLemeiterDAortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritisJ Cell Mol Med2016208556326859834 </plain></SENT>
</text></ref><ref id="ref26"><text><SENT sid="482" pm="."><plain>26DiYMChowVDYangLPZhouSFStructure, function, regulation and polymorphism of human cytochrome P450 2A6Curr Drug Metab2009107548019702528 </plain></SENT>
</text></ref><ref id="ref27"><text><SENT sid="483" pm="."><plain>27DingGXuWLiuHCYP1A1 MspI polymorphism is associated with prostate cancer susceptibility: evidence from a meta-analysisMol Biol Rep20134034839123475304 </plain></SENT>
</text></ref><ref id="ref28"><text><SENT sid="484" pm="."><plain>28DoMTKimHGTranTTMetformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expressionToxicol Appl Pharmacol20142801384825110054 </plain></SENT>
</text></ref><ref id="ref29"><text><SENT sid="485" pm="."><plain>29DostalekMCourtMHYanBAkhlaghiFSignificantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitusBr J Pharmacol20111639374721323901 </plain></SENT>
</text></ref><ref id="ref30"><text><SENT sid="486" pm="."><plain>30ElfakiIAlmutairiMFMirRKhanRAbu-DuhierFMCytochrome P450 CYP1B1*2 gene and its Association with T2D in Tabuk Population, Northwestern Region of Saudi ArabiaAsian J Pharm Clin Res201811559 </plain></SENT>
</text></ref><ref id="ref31"><text><SENT sid="487" pm="."><plain>31ErcanBAyazLCicekDTamerLRole of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosisCell Biochem Funct2008263091317868191 </plain></SENT>
</text></ref><ref id="ref32"><text><SENT sid="488" pm="."><plain>32FarooqMKellyEJUnadkatJDCYP2D6 is inducible by endogenous and exogenous corticosteroidsDrug Metab Dispos201644750726965986 </plain></SENT>
</text></ref><ref id="ref33"><text><SENT sid="489" pm="."><plain>33FernandezEPerezRHernandezAFactors and mechanisms for pharmacokinetic differences between pediatric population and adultsPharmaceutics20113537224310425 </plain></SENT>
</text></ref><ref id="ref34"><text><SENT sid="490" pm="."><plain>34FerraldeschiRHowellSJThompsonAMNewmanWGAvoidance of CYP2D6 inhibitors in patients receiving tamoxifenJ Clin Oncol2010285845author reply e586 </plain></SENT>
</text></ref><ref id="ref35"><text><SENT sid="491" pm="."><plain>35FisslthalerBFlemingIBusseREDHF: a cytochrome P450 metabolite in coronary arteriesSemin Perinatol20002415910709852 </plain></SENT>
</text></ref><ref id="ref36"><text><SENT sid="492" pm="."><plain>36FlemingIMichaelisURBredenkotterDEndothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteriesCirc Res200188445111139472 </plain></SENT>
</text></ref><ref id="ref37"><text><SENT sid="493" pm="."><plain>37FuZMaYXieXA novel polymorphism of the CYP4A11 gene is associated with coronary artery diseaseClin Appl Thromb Hemost20131960522327816 </plain></SENT>
</text></ref><ref id="ref38"><text><SENT sid="494" pm="."><plain>38GomezLKovacJRLambDJCYP17A1 inhibitors in castration-resistant prostate cancerSteroids20159580725560485 </plain></SENT>
</text></ref><ref id="ref39"><text><SENT sid="495" pm="."><plain>39GonzalezFJRole of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1Mutat Res20055691011015603755 </plain></SENT>
</text></ref><ref id="ref40"><text><SENT sid="496" pm="."><plain>40GuengerichFPMechanisms of cytochrome P450 substrate oxidation: MiniReviewJ Biochem Mol Toxicol200721163817936929 </plain></SENT>
</text></ref><ref id="ref41"><text><SENT sid="497" pm="."><plain>41GuengerichFPIntersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates, relevance to toxicity and drug interactionsChem Res Toxicol20173021227472660 </plain></SENT>
</text></ref><ref id="ref42"><text><SENT sid="498" pm="."><plain>42HakkolaJPasanenMPelkonenOExpression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cellsCarcinogenesis19971839179054634 </plain></SENT>
</text></ref><ref id="ref43"><text><SENT sid="499" pm="."><plain>43HalbergRBLarsenMCElmergreenTLCyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substratesCancer Res2008687394740218794127 </plain></SENT>
</text></ref><ref id="ref44"><text><SENT sid="500" pm="."><plain>44HazlehurstJMWoodsCMarjotTCobboldJFTomlinsonJWNon-alcoholic fatty liver disease and diabetesMetabolism2016651096110826856933 </plain></SENT>
</text></ref><ref id="ref45"><text><SENT sid="501" pm="."><plain>45HeXFengSRole of metabolic enzymes P450 (CYP) on activating procarcinogen and their polymorphisms on the risk of cancersCurr Drug Metab2015168506326652254 </plain></SENT>
</text></ref><ref id="ref46"><text><SENT sid="502" pm="."><plain>46Hoyo-VadilloCGarcia-MenaJValladaresAAssociation of CYP2C19 genotype with type 2 diabetesHealth20102118490 </plain></SENT>
</text></ref><ref id="ref47"><text><SENT sid="503" pm="."><plain>47HukkanenJJacobPBenowitzNLMetabolism and disposition kinetics of nicotinePharmacol Rev2005577911515734728 </plain></SENT>
</text></ref><ref id="ref48"><text><SENT sid="504" pm="."><plain>48ImigJDEpoxyeicosatrienoic acids and 20-Hydroxyeicosatetraenoic acid on endothelial and vascular functionAdv Pharmacol2016771054127451096 </plain></SENT>
</text></ref><ref id="ref49"><text><SENT sid="505" pm="."><plain>49Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J2005561315492763 </plain></SENT>
</text></ref><ref id="ref50"><text><SENT sid="506" pm="."><plain>50Ingelman-SundbergMOscarsonMMcLellanRAPolymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatmentTrends Pharmacol Sci199920342910431214 </plain></SENT>
</text></ref><ref id="ref51"><text><SENT sid="507" pm="."><plain>51IyanagiTMolecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxificationInt Rev Cytol20072603511217482904 </plain></SENT>
</text></ref><ref id="ref52"><text><SENT sid="508" pm="."><plain>52IzawaDPinesJHow APC/C-Cdc20 changes its substrate specificity in mitosisNat Cell Biol2011132233321336306 </plain></SENT>
</text></ref><ref id="ref53"><text><SENT sid="509" pm="."><plain>53JiangRYamaoriSOkamotoYYamamotoIWatanabeKCannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19Drug Metab Pharmacokinet201328332823318708 </plain></SENT>
</text></ref><ref id="ref54"><text><SENT sid="510" pm="."><plain>54JohanssonIIngelman-SundbergMGenetic polymorphism and toxicology--with emphasis on cytochrome p450Toxicol Sci201112011321149643 </plain></SENT>
</text></ref><ref id="ref55"><text><SENT sid="511" pm="."><plain>55JonsdottirSORingstedTNikolovNGIdentification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysisBioorg Med Chem20122020425322364953 </plain></SENT>
</text></ref><ref id="ref56"><text><SENT sid="512" pm="."><plain>56KanebrattKPDiczfalusyUBackstromTCytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterolClin Pharmacol Ther2008845899418650803 </plain></SENT>
</text></ref><ref id="ref57"><text><SENT sid="513" pm="."><plain>57KiddRSStraughnABMeyerMCPharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allelePharmacogenetics19999718010208645 </plain></SENT>
</text></ref><ref id="ref58"><text><SENT sid="514" pm="."><plain>58KoonrungsesomboonNKhatsriRWongchompooPTeekachunhateanSThe impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysisPharmacogenomics J201710113 </plain></SENT>
</text></ref><ref id="ref59"><text><SENT sid="515" pm="."><plain>59KotlyarMBrauerLHTracyTSInhibition of CYP2D6 activity by bupropionJ Clin Psychopharmacol200525226915876900 </plain></SENT>
</text></ref><ref id="ref60"><text><SENT sid="516" pm="."><plain>60KrishnamurthyKGlaserSAlpiniGDHeat shock factor-1 knockout enhances cholesterol 7alpha-hydroxylase (CYP7A1) and multidrug transporter (MDR1) gene expressions to attenuate atherosclerosisCardiovasc Res2016111748327131506 </plain></SENT>
</text></ref><ref id="ref61"><text><SENT sid="517" pm="."><plain>61LeeSJClinical application of CYP2C19 pharmacogenetics toward more personalized medicineFront Genet2012331823378847 </plain></SENT>
</text></ref><ref id="ref62"><text><SENT sid="518" pm="."><plain>62LeskelaSHonradoEMontero-CondeCCytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancerEndocr Relat Cancer2007146455417914095 </plain></SENT>
</text></ref><ref id="ref63"><text><SENT sid="519" pm="."><plain>63LeungTRajendranRSinghSCytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cellsBreast Cancer Res201315R10724207099 </plain></SENT>
</text></ref><ref id="ref64"><text><SENT sid="520" pm="."><plain>64LiTMatozelMBoehmeSOverexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasisHepatology201153996100621319191 </plain></SENT>
</text></ref><ref id="ref65"><text><SENT sid="521" pm="."><plain>65LocusonCWWahlstromJLRockDARockDAJonesJPA new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivativesDrug Metab Dispos2003319677112814975 </plain></SENT>
</text></ref><ref id="ref66"><text><SENT sid="522" pm="."><plain>66LuomaPVCytochrome P450-physiological key factor against cholesterol accumulation and the atherosclerotic vascular processAnn Med2007393597017701478 </plain></SENT>
</text></ref><ref id="ref67"><text><SENT sid="523" pm="."><plain>67LuthraADenisovIGSligarSGSpectroscopic features of cytochrome P450 reaction intermediatesArch Biochem Biophys2011507263521167809 </plain></SENT>
</text></ref><ref id="ref68"><text><SENT sid="524" pm="."><plain>68MaMKWooMHMcLeodHLGenetic basis of drug metabolismAm J Health Syst Pharm2002592061912434718 </plain></SENT>
</text></ref><ref id="ref69"><text><SENT sid="525" pm="."><plain>69MadanayakeTWLindquistIEDevittNPMudgeJRowlandAMA transcriptomic approach to elucidate the physiological significance of human cytochrome P450 2S1 in bronchial epithelial cellsBMC Genomics20131483324279958 </plain></SENT>
</text></ref><ref id="ref70"><text><SENT sid="526" pm="."><plain>70MahdiFRazaSTRizviSAbbasSKaroliRDistribution of genetic polymorphisms in drug metabolizing gene cytochrome P450 (CYP2C8*3 and CYP2C9*2) in a North Indian type 2 diabetes populationExplor Res Hypothesis Med20161426 </plain></SENT>
</text></ref><ref id="ref71"><text><SENT sid="527" pm="."><plain>71McFadyenMCMcLeodHLJacksonFCCytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistanceBiochem Pharmacol2001622071211389879 </plain></SENT>
</text></ref><ref id="ref72"><text><SENT sid="528" pm="."><plain>72McFadyenMCMelvinWTMurrayGICytochrome P450 CYP1B1 activity in renal cell carcinomaBr J Cancer2004919667115280921 </plain></SENT>
</text></ref><ref id="ref73"><text><SENT sid="529" pm="."><plain>73McFadyenMCMelvinWTMurrayGICytochrome P450 enzymes: novel options for cancer therapeuticsMol Cancer Ther200433637115026557 </plain></SENT>
</text></ref><ref id="ref74"><text><SENT sid="530" pm="."><plain>74MengFDMaPSuiCGTianXJiangYHAssociation between cytochrome P450 1A1 (CYP1A1) gene polymorphisms and the risk of renal cell carcinoma: a meta-analysisSci Rep20155810825630554 </plain></SENT>
</text></ref><ref id="ref75"><text><SENT sid="531" pm="."><plain>75MinersJOBirkettDJCytochrome P4502C9: an enzyme of major importance in human drug metabolismBr J Clin Pharmacol199845525389663807 </plain></SENT>
</text></ref><ref id="ref76"><text><SENT sid="532" pm="."><plain>76MisasiSMartiniGPaolettiOVKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patientsMedicine (Baltimore)201695e545128033245 </plain></SENT>
</text></ref><ref id="ref77"><text><SENT sid="533" pm="."><plain>77MitsuiYChangIFukuharaSCYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinomaBMC Cancer20151594226626260 </plain></SENT>
</text></ref><ref id="ref78"><text><SENT sid="534" pm="."><plain>78MittalBTulsyanSKumarSMittalRDAgarwalGCytochrome P450 in cancer susceptibility and treatmentAdv Clin Chem2015717713926411412 </plain></SENT>
</text></ref><ref id="ref79"><text><SENT sid="535" pm="."><plain>79Mohd SiddiqueMUMcCannGJSonawaneVRQuinazoline derivatives as selective CYP1B1 inhibitorsEur J Med Chem2017130320728259840 </plain></SENT>
</text></ref><ref id="ref80"><text><SENT sid="536" pm="."><plain>80MoorthyBChuCCarlinDJPolycyclic aromatic hydrocarbons: from metabolism to lung cancerToxicol Sci201514551525911656 </plain></SENT>
</text></ref><ref id="ref81"><text><SENT sid="537" pm="."><plain>81MoritaJKobayashiKWanibuchiAA novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylationDrug Metab Pharmacokinet200419236815499191 </plain></SENT>
</text></ref><ref id="ref82"><text><SENT sid="538" pm="."><plain>82MurrayGIMcFadyenMCMitchellRTCytochrome P450 CYP3A in human renal cell cancerBr J Cancer19997918364210206301 </plain></SENT>
</text></ref><ref id="ref83"><text><SENT sid="539" pm="."><plain>83MurrayGIPatimallaSStewartKNMillerIDHeysSDProfiling the expression of cytochrome P450 in breast cancerHistopathology2010572021120716162 </plain></SENT>
</text></ref><ref id="ref84"><text><SENT sid="540" pm="."><plain>84MurrayGITaylorMCMcFadyenMCTumor-specific expression of cytochrome P450 CYP1B1Cancer Res1997573026319230218 </plain></SENT>
</text></ref><ref id="ref85"><text><SENT sid="541" pm="."><plain>85NebertDWDaltonTPOkeyABGonzalezFJRole of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancerJ Biol Chem2004279238475015028720 </plain></SENT>
</text></ref><ref id="ref86"><text><SENT sid="542" pm="."><plain>86NebertDWRussellDWClinical importance of the cytochromes P450Lancet200236011556212387968 </plain></SENT>
</text></ref><ref id="ref87"><text><SENT sid="543" pm="."><plain>87NelsonDRZeldinDCHoffmanSMComparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variantsPharmacogenetics20041411815128046 </plain></SENT>
</text></ref><ref id="ref88"><text><SENT sid="544" pm="."><plain>88NeveEPIngelman-SundbergMCytochrome P450 proteins: retention and distribution from the endoplasmic reticulumCurr Opin Drug Discov Devel2010137885 </plain></SENT>
</text></ref><ref id="ref89"><text><SENT sid="545" pm="."><plain>89NiemelÃ¤OParkkilaSJuvonenROCytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseasesJ Hepatol20003389390111131450 </plain></SENT>
</text></ref><ref id="ref90"><text><SENT sid="546" pm="."><plain>90NinomiyaHMamiyaKMatsuoSGenetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxicationTher Drug Monit200022230210774639 </plain></SENT>
</text></ref><ref id="ref91"><text><SENT sid="547" pm="."><plain>91NissenSENichollsSJWolskiKEffects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trialsJAMA200729713627317384435 </plain></SENT>
</text></ref><ref id="ref92"><text><SENT sid="548" pm="."><plain>92OhSJChoiJMYunKUHepatic expression of cytochrome P450 in type 2 diabetic Goto-Kakizaki ratsChem Biol Interact2012195173922244987 </plain></SENT>
</text></ref><ref id="ref93"><text><SENT sid="549" pm="."><plain>93Ortiz de MontellanoPRHydrocarbon hydroxylation by cytochrome P450 enzymesChem Rev20101109324819769330 </plain></SENT>
</text></ref><ref id="ref94"><text><SENT sid="550" pm="."><plain>94OscarsonMMcLellanRAGullstÃ©nHIdentification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Lett1999460321710544257 </plain></SENT>
</text></ref><ref id="ref95"><text><SENT sid="551" pm="."><plain>95OyamaTMoritaMIsseTImmunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancerFront Biosci20051011566115769614 </plain></SENT>
</text></ref><ref id="ref96"><text><SENT sid="552" pm="."><plain>96PattenCJSmithTJFriesenMJEvidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomesCarcinogenesis1997181623309276639 </plain></SENT>
</text></ref><ref id="ref97"><text><SENT sid="553" pm="."><plain>97PavekPDvorakZXensobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissuesCurr Drug Metab200891294318288955 </plain></SENT>
</text></ref><ref id="ref98"><text><SENT sid="554" pm="."><plain>98PerssonASimSCVirdingSDecreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 geneMol Psychiatry2014197334123877834 </plain></SENT>
</text></ref><ref id="ref99"><text><SENT sid="555" pm="."><plain>99PeterssonHSteroid metabolizing cytochrome P450 (CYP) enzymes in the maintenance of cholesterol and sex hormonelevels PhD, Uppsala University2009 </plain></SENT>
</text></ref><ref id="ref100"><text><SENT sid="556" pm="."><plain>100PikulevaIAWatermanMRCytochromes p450: roles in diseasesJ Biol Chem201328817091823632021 </plain></SENT>
</text></ref><ref id="ref101"><text><SENT sid="557" pm="."><plain>101PirmohamedMParkBKCytochrome P450 enzyme polymorphisms and adverse drug reactionsToxicology2003192233214511900 </plain></SENT>
</text></ref><ref id="ref102"><text><SENT sid="558" pm="."><plain>102PollastroCZivielloCCostaVCiccodicolaAPharmacogenomics of drug response in type 2 diabetes: Toward the definition of tailored therapies?PPAR Res2015201541514926161088 </plain></SENT>
</text></ref><ref id="ref103"><text><SENT sid="559" pm="."><plain>103PolonikovAKharchenkoABykanovaMPolymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian populationGene2017627451928687336 </plain></SENT>
</text></ref><ref id="ref104"><text><SENT sid="560" pm="."><plain>104PortJLYamaguchiKDuBTobacco smoke induces CYP1B1 in the aerodigestive tractCarcinogenesis20042522758115297370 </plain></SENT>
</text></ref><ref id="ref105"><text><SENT sid="561" pm="."><plain>105PorterTDCoonMJCytochrome P-450 multiplicity of isoforms, substrates, and catalytic and regulatory mechanismsJ Biol Chem199126613469721856184 </plain></SENT>
</text></ref><ref id="ref106"><text><SENT sid="562" pm="."><plain>106PullingerCREngCSalenGHuman cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotypeJ Clin Invest20021101091712093894 </plain></SENT>
</text></ref><ref id="ref107"><text><SENT sid="563" pm="."><plain>107QrafliMAmarYBourkadiJThe CYP7A1 gene rs380âvariant is associated with susceptibility of tuberculosis in Moroccan populationPan Afr Med J2014181 </plain></SENT>
</text></ref><ref id="ref108"><text><SENT sid="564" pm="."><plain>108RahnastoMWittekindtCJuvonenROIdentification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approachPharmacogenomics J200883283817923852 </plain></SENT>
</text></ref><ref id="ref109"><text><SENT sid="565" pm="."><plain>109RaiRSharmaKLMisraSKumarAMittalBCYP17 polymorphism (rs743572) is associated with increased risk of gallbladder cancer in tobacco usersTumour Biol2014356531724687554 </plain></SENT>
</text></ref><ref id="ref110"><text><SENT sid="566" pm="."><plain>110RaunioHRautioAGullstÃ©nHPelkonenOPolymorphisms of CYP2A6 and its practical consequencesBr J Clin Pharmacol2001523576311678779 </plain></SENT>
</text></ref><ref id="ref111"><text><SENT sid="567" pm="."><plain>111RenJChenGGLiuYCytochrome P450 1A2 metabolizes 17beta-estradiol to suppress hepatocellular carcinomaPLoS One201611e015386327093553 </plain></SENT>
</text></ref><ref id="ref112"><text><SENT sid="568" pm="."><plain>112RenaudHJCuiJYKhanMKlaassenCDTissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in miceToxicol Sci20111242617721920951 </plain></SENT>
</text></ref><ref id="ref113"><text><SENT sid="569" pm="."><plain>113RendellMThe role of sulphonylureas in the management of type 2 diabetes mellitusDrugs20046413395815200348 </plain></SENT>
</text></ref><ref id="ref114"><text><SENT sid="570" pm="."><plain>114RettieAEJonesJPClinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogeneticsAnnu Rev Pharmacol Toxicol2005454779415822186 </plain></SENT>
</text></ref><ref id="ref115"><text><SENT sid="571" pm="."><plain>115ReynaldRLSansenSStoutCDJohnsonEFStructural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19J Biol Chem2012287445819123118231 </plain></SENT>
</text></ref><ref id="ref116"><text><SENT sid="572" pm="."><plain>116RiveraSPWangFSaarikoskiSTA novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxiaJ Biol Chem2007282108819317277313 </plain></SENT>
</text></ref><ref id="ref117"><text><SENT sid="573" pm="."><plain>117RochatBMorsmanJMMurrayGIFiggWDMcLeodHLHuman CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?J Pharmacol Exp Ther20012965374111160641 </plain></SENT>
</text></ref><ref id="ref118"><text><SENT sid="574" pm="."><plain>118RowlandPBlaneyFESmythMGCrystal structure of human cytochrome P450 2D6J Biol Chem200628176142216352597 </plain></SENT>
</text></ref><ref id="ref119"><text><SENT sid="575" pm="."><plain>119SachseCBrockmÃ¶llerJBauerSRootsIFunctional significance of a C--&gt;A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeineBr J Clin Pharmacol199947445910233211 </plain></SENT>
</text></ref><ref id="ref120"><text><SENT sid="576" pm="."><plain>120HamedSMindySKEstrogen metabolism and breast cancerCancer Lett20153562314324784887 </plain></SENT>
</text></ref><ref id="ref121"><text><SENT sid="577" pm="."><plain>121SanfordJCGuoYSadeeWWangDRegulatory polymorphisms in CYP2C19 affecting hepatic expressionDrug Metabol Drug Interact201328233023412869 </plain></SENT>
</text></ref><ref id="ref122"><text><SENT sid="578" pm="."><plain>122SansenSYanoJKReynaldRLAdaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2J Biol Chem2007282143485517311915 </plain></SENT>
</text></ref><ref id="ref123"><text><SENT sid="579" pm="."><plain>123SchlingmannKPKaufmannMWeberSMutations in CYP24A1 and idiopathic infantile hypercalcemiaN Engl J Med20113654102121675912 </plain></SENT>
</text></ref><ref id="ref124"><text><SENT sid="580" pm="."><plain>124SeowAZhaoBLeeEJCytochrome P4501A2 (CYP1A2) activity and lung cancer risk: a preliminary study among Chinese women in SingaporeCarcinogenesis200122673711285205 </plain></SENT>
</text></ref><ref id="ref125"><text><SENT sid="581" pm="."><plain>125ShimadaTFujii-KuriyamaYMetabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1Cancer Sci2004951614720319 </plain></SENT>
</text></ref><ref id="ref126"><text><SENT sid="582" pm="."><plain>126ShimadaTMurajamaNTanakaKInteraction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activityChem Res Toxicol20082123132319548353 </plain></SENT>
</text></ref><ref id="ref127"><text><SENT sid="583" pm="."><plain>127ShimadaTMurayamaNYamazakiHMetabolic activation of polycyclic aromatic hydrocarbons and aryl and heterocyclic amines by human cytochromes P450 2A13 and 2A6Chem Res Toxicol2013265293723432465 </plain></SENT>
</text></ref><ref id="ref128"><text><SENT sid="584" pm="."><plain>128ShimadaTOdaYGillamEMGuengerichFPInoueKMetabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009Drug Metab Dispos20012911768211502724 </plain></SENT>
</text></ref><ref id="ref129"><text><SENT sid="585" pm="."><plain>129SibbingDKochWGebhardDCytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placementCirculation2010121512820083681 </plain></SENT>
</text></ref><ref id="ref130"><text><SENT sid="586" pm="."><plain>130SilvestriLSonzogniLDe SilvestriACYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancerInt J Cancer2003104310712569554 </plain></SENT>
</text></ref><ref id="ref131"><text><SENT sid="587" pm="."><plain>131SimSCIngelman-SundbergMThe human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effectsHum Genomics201042788120511141 </plain></SENT>
</text></ref><ref id="ref132"><text><SENT sid="588" pm="."><plain>132SimSCIngelman-SundbergMUpdate on allele nomenclature for human cytochromes P450 and the human cytochrome P450 allele (CYP-allele) nomenclature databaseMethods Mol Biol2013987251923475683 </plain></SENT>
</text></ref><ref id="ref133"><text><SENT sid="589" pm="."><plain>133SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med20093603637519106083 </plain></SENT>
</text></ref><ref id="ref134"><text><SENT sid="590" pm="."><plain>134SindhuRKKooJRSindhuKKDifferential regulation of hepatic cytochrome P450 monooxygenases in streptozotocin-induced diabetic ratsFree Radic Res200640921817015271 </plain></SENT>
</text></ref><ref id="ref135"><text><SENT sid="591" pm="."><plain>135SirotinaSPonomarenkoIKharchenkoAA novel polymorphism in the promoter of the CYP4A11 gene is associated with susceptibility to coronary artery diseaseDis Markers20182018581280229484037 </plain></SENT>
</text></ref><ref id="ref136"><text><SENT sid="592" pm="."><plain>136SissungTMPriceDKSparreboomAFiggWDPharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic interventionMol Cancer Res200641355016547151 </plain></SENT>
</text></ref><ref id="ref137"><text><SENT sid="593" pm="."><plain>137SistonenJFuselliSPaloJUPharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scalesPharmacogenet Genomics200919170919151603 </plain></SENT>
</text></ref><ref id="ref138"><text><SENT sid="594" pm="."><plain>138SkeochSHaqueSPembertonPBruceINCell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLELupus2014238192424647443 </plain></SENT>
</text></ref><ref id="ref139"><text><SENT sid="595" pm="."><plain>139SÅowikowskiBKGaÅÄckiBDyszkiewiczWJagodziÅskiPPDecreased expression of cytochrome p450 1B1 in non-small cell lung cancerBiomed Pharmacother2017953394528858732 </plain></SENT>
</text></ref><ref id="ref140"><text><SENT sid="596" pm="."><plain>140SmerdovÃ¡LÅ merdovÃ¡JKabÃ¡tkovÃ¡MUpregulation of CYP1B1 expression by inflammatory cytokines is mediated by the p38 MAP kinase signal transduction pathwayCarcinogenesis20143525344325233930 </plain></SENT>
</text></ref><ref id="ref141"><text><SENT sid="597" pm="."><plain>141SongCYGhafoorKGhafoorHUCytochrome P450 1B1 contributes to the development of atherosclerosis and hypertension in apolipoprotein E-deficient MiceHypertension2016672061326573711 </plain></SENT>
</text></ref><ref id="ref142"><text><SENT sid="598" pm="."><plain>142SuJMLinPWangCKChangHOverexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic targetAnticancer Res2009295091519331196 </plain></SENT>
</text></ref><ref id="ref143"><text><SENT sid="599" pm="."><plain>143SuTBaoZZhangQYHuman cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneCancer Res2000605074911016631 </plain></SENT>
</text></ref><ref id="ref144"><text><SENT sid="600" pm="."><plain>144SunJZhangHGaoMAssociation between CYP17 T-34C rs743572 and breast cancer riskOncotarget2018942001329423115 </plain></SENT>
</text></ref><ref id="ref145"><text><SENT sid="601" pm="."><plain>145SunLFanXExpression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significanceJ Biomed Res201327202723720675 </plain></SENT>
</text></ref><ref id="ref146"><text><SENT sid="602" pm="."><plain>146SunmanJAHawkeRLLeCluyseELKashubaADKupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytesDrug Metab Dispos2004323596314977871 </plain></SENT>
</text></ref><ref id="ref147"><text><SENT sid="603" pm="."><plain>147ThelenKDressmanJBCytochrome P450-mediated metabolism in the human gut wallJ Pharm Pharmacol2009615415819405992 </plain></SENT>
</text></ref><ref id="ref148"><text><SENT sid="604" pm="."><plain>148TirochKASibbingDKochWProtective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular eventsAm Heart J20101605061220826260 </plain></SENT>
</text></ref><ref id="ref149"><text><SENT sid="605" pm="."><plain>149TokizaneTShiinaHIgawaMCytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancerClin Cancer Res2005115793580116115918 </plain></SENT>
</text></ref><ref id="ref150"><text><SENT sid="606" pm="."><plain>150TousoulisDOikonomouEEconomouEKCreaFKaskiJCInflammatory cytokines in atherosclerosis: current therapeutic approachesEur Heart J20163717233226843277 </plain></SENT>
</text></ref><ref id="ref151"><text><SENT sid="607" pm="."><plain>151TsuchiyaYNakajimaMKyoSHuman CYP1B1 is regulated by estradiol via estrogen receptorCancer Res20046431192515126349 </plain></SENT>
</text></ref><ref id="ref152"><text><SENT sid="608" pm="."><plain>152UeharaSUnoYInoueTNovel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazoleDrug Metab Dispos20154314081626228688 </plain></SENT>
</text></ref><ref id="ref153"><text><SENT sid="609" pm="."><plain>153Ur RasheedMSMishraAKSinghMPCytochrome P450 2D6 and parkinson's disease: polymorphism, metabolic role, risk and protectionNeurochem Res20174233536128871472 </plain></SENT>
</text></ref><ref id="ref154"><text><SENT sid="610" pm="."><plain>154VaclavikovaRHubackovaMStribrna-SarmanovaJRNA expression of cytochrome P450 in breast cancer patientsAnticancer Res20072744435018214058 </plain></SENT>
</text></ref><ref id="ref155"><text><SENT sid="611" pm="."><plain>155Van BoovenDMarshSMcLeodHCytochrome P450 2C9-CYP2C9Pharmacogenet Genomics2010202778120150829 </plain></SENT>
</text></ref><ref id="ref156"><text><SENT sid="612" pm="."><plain>156VasanthanathanPTaboureauOOostenbrinkCClassification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniquesDrug Metab Dispos2009376586419056915 </plain></SENT>
</text></ref><ref id="ref157"><text><SENT sid="613" pm="."><plain>157VijayalakshmiKVettriselviVKrishnanMCytochrome p4501A1 gene variants as susceptibility marker for prostate cancerCancer Biomark20051251817192049 </plain></SENT>
</text></ref><ref id="ref158"><text><SENT sid="614" pm="."><plain>158WangASavasUStoutCDJohnsonEFStructural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1J Biol Chem201128657364321147782 </plain></SENT>
</text></ref><ref id="ref159"><text><SENT sid="615" pm="."><plain>159WangBYangLPZhangXZNew insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzymeDrug Metab Rev20094157364319645588 </plain></SENT>
</text></ref><ref id="ref160"><text><SENT sid="616" pm="."><plain>160WangHZhangZHanSCYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case-control studiesBMC Cancer20121252823157985 </plain></SENT>
</text></ref><ref id="ref161"><text><SENT sid="617" pm="."><plain>161WangHXLiuXXuCJInduction of liver cytochrome P450 1A2 expression by flutamide in ratsActa Pharmacol Sin2005261382616225762 </plain></SENT>
</text></ref><ref id="ref162"><text><SENT sid="618" pm="."><plain>162WangSYXingPFZhangCYDengBQAssociation of CYP2J2 gene polymorphisms with ischemic stroke and stroke subtypes in Chinese populationMedicine (Baltimore)201796e626628272236 </plain></SENT>
</text></ref><ref id="ref163"><text><SENT sid="619" pm="."><plain>163WangXLiJDongGYueJThe endogenous substrates of brain CYP2DEur J Pharmacol20147242111824374199 </plain></SENT>
</text></ref><ref id="ref164"><text><SENT sid="620" pm="."><plain>164WangZHallSDMayaJFDiabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humansBr J Clin Pharmacol200355778512534643 </plain></SENT>
</text></ref><ref id="ref165"><text><SENT sid="621" pm="."><plain>165WenzlaffASCoteMLBockCHCYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based studyCarcinogenesis20052622071216051642 </plain></SENT>
</text></ref><ref id="ref166"><text><SENT sid="622" pm="."><plain>166WesterMRYanoJKSchochGAThe structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolutionJ Biol Chem200427935630715181000 </plain></SENT>
</text></ref><ref id="ref167"><text><SENT sid="623" pm="."><plain>167WhiteCCFengQCupplesLACYP4A11 variant is associated with high-density lipoprotein cholesterol in womenPharmacogenomics J201313445121912424 </plain></SENT>
</text></ref><ref id="ref168"><text><SENT sid="624" pm="."><plain>168WilliamsPACosmeJWardACrystal structure of human cytochrome P450 2C9 with bound warfarinNature2003424464812861225 </plain></SENT>
</text></ref><ref id="ref169"><text><SENT sid="625" pm="."><plain>169WomackCJSaundersMJBechtelMKThe influence of a CYP1A2 polymorphism on the ergogenic effects of caffeineJ Int Soc Sports Nutr20129722420682 </plain></SENT>
</text></ref><ref id="ref170"><text><SENT sid="626" pm="."><plain>170YamadaYMatsuoHWatanabeSAssociation of a polymorphism of CYP3A4 with type 2 diabetes mellitusInt J Mol Med200720703717912464 </plain></SENT>
</text></ref><ref id="ref171"><text><SENT sid="627" pm="."><plain>171YanoJKHsuMHGriffinKJStoutCDJohnsonEFStructures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalenNat Struct Mol Biol200512822316086027 </plain></SENT>
</text></ref><ref id="ref172"><text><SENT sid="628" pm="."><plain>172YuAKnellerBMRettieAEHainingRLExpression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoformsJ Pharmacol Exp Ther20023031291130012438554 </plain></SENT>
</text></ref><ref id="ref173"><text><SENT sid="629" pm="."><plain>173YuCYanQFuCCYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese populationLipids Health Dis2014138324886380 </plain></SENT>
</text></ref><ref id="ref174"><text><SENT sid="630" pm="."><plain>174YuPJChenWGFengQLAssociation between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancerMed Sci Monit2015212394525619313 </plain></SENT>
</text></ref><ref id="ref175"><text><SENT sid="631" pm="."><plain>175ZangerUMSchwabMCytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variationPharmacol Ther20131381034123333322 </plain></SENT>
</text></ref><ref id="ref176"><text><SENT sid="632" pm="."><plain>176ZengWGuoY2ChenPCYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsJ Diabetes Investig201677648 </plain></SENT>
</text></ref><ref id="ref177"><text><SENT sid="633" pm="."><plain>177ZhangHJinLMuTAssociations of CYP4A11 gene-gene and gene-smoking interactions with essential hypertension in the male eastern Chinese Han populationClin Exp Hypertens2017394485328534704 </plain></SENT>
</text></ref><ref id="ref178"><text><SENT sid="634" pm="."><plain>178ZhengJYanHShiLThe CYP19A1 rs3751592 variant confers susceptibility to Alzheimer disease in the Chinese Han populationMedicine (Baltimore)201695e474227583919 </plain></SENT>
</text></ref><ref id="ref179"><text><SENT sid="635" pm="."><plain>179ZhouBSongZQianMFunctional polymorphisms in the CYP2C19 gene contribute to digestive system cancer risk: evidence from 11,042 subjectsPLoS One20138e6686523874401 </plain></SENT>
</text></ref><ref id="ref180"><text><SENT sid="636" pm="."><plain>180ZhouSFYangLPZhouZWLiuYHChanEInsights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2AAPS J2009114819419590965 </plain></SENT>
</text></ref><ref id="ref181"><text><SENT sid="637" pm="."><plain>181ZhouSFZhouZWYangLPCaiJPSubstrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug developmentCurr Med Chem2009163480367519515014 </plain></SENT>
</text></ref><ref id="ref182"><text><SENT sid="638" pm="."><plain>182ZhuLRThomasPELuGCYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibodyDrug Metab Dispos2006341672616815959 </plain></SENT>
</text></ref><ref id="ref183"><text><SENT sid="639" pm="."><plain>183ZhuZYMuYQFuXMLiSMZhaoFXAssociation of CYP1B1 gene polymorphisms and the positive expression of estrogen alpha and estrogen beta with endometrial cancer riskEur J Gynaecol Oncol2011321889121614911 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
